Development and Validation of the Barriers Questionnaire - Juvenile Idiopathic Arthritis, Patient- and Parent-report Measures by Tsai, Michele
 
 
 
 
Development and Validation of the Barriers Questionnaire – Juvenile Idiopathic Arthritis, 
Patient- and Parent-report Measures 
By 
Michele S. Tsai 
Submitted to the graduate degree program in Psychology and the Graduate Faculty of the 
University of Kansas in partial fulfillment of the requirements for the degree of Master of Arts. 
 
 
________________________________        
Chairperson Michael Rapoff, Ph.D.             
 
________________________________        
Douglas Denney, Ph.D. 
 
________________________________        
John Belmont, Ph.D. 
 
 
 
Date Defended: June 7, 2013 
 
  
ii 
 
 
 
The Thesis Committee for Michele S. Tsai 
certifies that this is the approved version of the following thesis: 
 
 
 
Development and Validation of the Barriers Questionnaire – Juvenile Idiopathic Arthritis, 
Patient- and Parent-report Measures 
 
 
 
 
 
 
      ________________________________ 
 Chairperson Michael Rapoff, Ph.D. 
 
 
       
Date approved: June 7, 2013 
 
 
iii 
 
Abstract 
Medication adherence among patients with Juvenile Idiopathic Arthritis (JIA) varies widely, 
suggesting some patients may not benefit fully from their medication regimens.  Assessment of 
adherence barriers would assist clinicians and families in determining targets for adherence-
promoting interventions.  In this study the psychometric properties of the Barriers Questionnaire 
– JIA (BQ-JIA, patient- and parent-report measures) were tested.  Thirty-five patients with JIA 
and their parents completed measures of adherence (self-report and pill count), barriers, and 
beliefs about medication taking.  The 18-item barriers measures demonstrated variable internal 
consistency (Cronbach’s α = 0.41 and 0.72, patient and parent versions) and strong test-retest 
reliability over a brief period (median = 19 days).  Concurrent, convergent, and divergent 
validity were supported through correlations with other study measures.  Predictive and 
incremental validity were tentatively supported.  Patient age moderated the relationship between 
parent-reported barriers and pill count adherence.  The BQ-JIA measures showed promise as 
clinically useful measures of adherence barriers. 
 Keywords: juvenile idiopathic arthritis, medication adherence, barriers 
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Development and Validation of the Barriers Questionnaire – Juvenile Idiopathic Arthritis, 
Patient- and Parent-report Measures 
Due to multiple diagnostic systems for defining the different chronic arthritides with 
childhood onset, prevalence estimates for these diseases vary (Manners & Bower, 2002; Centers 
for Disease Control and Prevention, 2010) but tend to be small compared with the prevalence of 
other pediatric chronic illnesses, such as asthma (Newacheck & Taylor, 1992).  However, 
chronic arthritis carries the risk of permanent physical disability.  Currently available medical 
treatments have the potential to control arthritis symptoms adequately and decrease risk of 
disability, but poor adherence to prescribed medical regimens may limit these benefits.  The 
Health Belief Model provides a well-researched theoretical framework for modeling 
relationships between different types of health beliefs and health behaviors (including regimen 
adherence).  Adult studies show that perceived barriers to performing a health behavior represent 
the type of health belief most predictive of engaging in health behaviors (Abraham & Sheeran, 
2005; Harrison, Mullen, & Green, 1992; Janz & Becker, 1984).  Developing measures that could 
reliably elicit perceptions of barriers to medication adherence from pediatric patients with 
arthritis and their parents may assist clinicians in tailoring adherence-improvement interventions 
to target barriers specifically relevant to individual patients and their families. 
After describing the classification systems, treatment components, and rates of adherence 
among pediatric patients with chronic arthritis, this author reviews the support for the 
relationship between barriers and health behaviors (including regimen adherence) as 
conceptualized in the Health Belief Model in adult and in pediatric studies.  This author then 
presents the results of a pilot study conducted to develop and test the psychometric properties of 
a new clinical tool, the Barriers Questionnaire – Juvenile Idiopathic Arthritis (BQ-JIA). 
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Childhood Chronic Arthritides 
Overview of classification systems and specific diseases. From the 1970s to the 1990s, 
physicians used two overlapping but distinct classification systems for determining specific 
pediatric arthritis diagnoses.  These specific arthritides were differentiated on the basis of the 
number and types of joints affected by inflammation, organ systems affected in addition to the 
musculoskeletal system, and laboratory test results observed during the first six months of 
disease activity.  The American College of Rheumatology’s criteria for Juvenile Rheumatoid 
Arthritis (JRA) included arthritides with symptom onset before age 16 and minimum duration of 
six weeks.  Systemic-onset, polyarticular, and pauciarticular (oligoarticular) were the three 
recognized onset types of JRA.  Though the European League Against Rheumatism’s criteria for 
Juvenile Chronic Arthritis (JCA) included the same age of symptom onset as JRA, the minimum 
duration of diseases classified under JCA was twelve weeks.  Additionally, the criteria included 
Juvenile Ankylosing Spondylitis, Juvenile Psoriatic Arthritis, and the Inflammatory Bowel 
Diseases among the six subtypes of JCA, while the JRA criteria specifically excluded these 
diseases (Petty & Cassidy, 2010). 
Since 1994, a third typology, developed by the International League of Associations for 
Rheumatology’s Pediatric Standing Committee (Fink, 1995), has come into use, replacing the 
JRA and JCA systems.  Juvenile Idiopathic Arthritis (JIA) remains a heterogeneous category 
encompassing arthritides of unknown origin with disease onset before age 16.  Six onset 
subtypes (systemic JIA, rheumatoid factor positive polyarthritis, enthesitis-related arthritis, 
oligoarthritis, rheumatoid factor negative polyarthritis, and psoriatic arthritis) and one course 
subtype (extended oligoarthritis course) constitute the specific arthritides classified within JIA.  
Four of the subtypes identify homogenous disease entities, namely, systemic JIA, rheumatoid 
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factor positive polyarthritis, enthesitis-related arthritis, and oligoarthritis.  Characteristic 
symptoms of systemic JIA include fever, rash, and serositis (inflammation of serous tissue) in 
addition to joint inflammation.  These symptoms are believed to constitute a polygenic 
autoinflammatory syndrome (Prakken, Albani, & Martini, 2011).  Approximately 10-20% of 
patients with JIA are diagnosed with systemic JIA (Petty et al., 2004).  Rheumatoid factor (RF) 
positive polyarthritis is the only form of JIA characterized by the presence of rheumatoid factor.  
Patients with RF-positive polyarthritis experience inflammation in five or more joints.  These 
commonly include joints in the hands, the wrists, the hips, the knees, the ankles, and the neck.  
About 5-10% of JIA patients are diagnosed with RF-positive polyarthritis (Petty et al., 2004).  
Enthesitis-related arthritis refers to an undifferentiated form of spondyloarthropathy.  Clinical 
features of the spondyloarthropathies include back pain due to inflammation of the joints or 
ligaments of the spine (axial symptoms) and peripheral arthritis (Dougados & Baeten, 2011).  
The prevalence of enthesitis-related arthritis is not known (Petty et al., 2004).  Oligoarthritis 
involves four or fewer active joints (usually larger joints) in the first six months.  It tends to 
affect more females than males and to have an early onset (typically before age six).  High 
concentrations of antinuclear antibodies (ANA) and a high risk of chronic iridocyclitis 
(inflammation of the eye’s iris and ciliary body) are other characteristics of oligoarthritis 
(Prakken et al., 2011).  The extended oligoarthritis course subtype represents a more severe form 
of oligoarthritis, as more joints become affected after the first six months; however, the other 
clinical features remain. Approximately 40-60% of JIA patients have oligoarthritis (Petty et al., 
2004). 
The subtypes identifying more heterogeneous disease groups are RF-negative 
polyarthritis (affecting 20-25% of JIA patients) and psoriatic arthritis (affecting 5% of JIA 
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patients; Petty et al., 2004).  One form of RF-negative polyarthritis resembles oligoarthritis but 
with a greater number of active joints, while the other form lacks ANA expression.  Psoriatic 
arthritis, which affects skin as well as joints, also has two forms: one resembles 
spondyloarthropathy and the other resembles ANA-positive oligoarthritis but affects smaller 
joints more often than larger ones (Prakken et al., 2011). 
The JIA subtypes together represent the most common childhood rheumatic diseases, 
with prevalence estimates ranging between 0.07 and 4.01 per 1000 children and annual incidence 
estimates ranging from 0.008 to 0.226 per 1000 children (Manners & Bower, 2002).  JIA is also 
a major source of short- and long-term disability (Rapoff, Belmont, Lindsley, & Olson, 2005).  
Over 20% of JIA patients suffer physical disability due to joint damage, and 10-70% of patients 
with JIA-related eye uveitis suffer visual impairment (Moorthy, Peterson, Hassett, & Lehman, 
2010).  Because no cure has been developed for these chronic diseases, the primary goals of 
medical treatment are to induce disease remission, manage pain, prevent joint deformities and 
preserve functionality, and treat systemic complications so that patients may experience normal 
growth and development (Petty & Cassidy; in Cassidy, Petty, Laxer, & Lindsley, 2010).   
Treatment regimen components.  JIA treatment regimens usually include medication 
and sometimes physical therapy or occupational therapy exercises and the use of joint supports.  
If needed, orthopedic surgery, nutritional support, and psychosocial support are also 
recommended.  Because medications are the most commonly prescribed treatments, medication 
nonadherence may significantly reduce the efficacy of the overall treatment regimen.  Treatment 
with medications occurs in a stepwise fashion in which nonsteroidal antiinflammatory drugs 
(NSAIDs) are initially prescribed and, if an adequate therapeutic response is not achieved, other 
types of medications are added (Rapoff & Lindsley, 2007). 
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NSAIDs are first-line medications used primarily for symptom relief.  They alleviate 
pain, stiffness, and fever, and they reduce inflammation by inhibiting proinflammatory pathways.  
NSAIDs are generally safe for long-term use but may cause gastrointestinal discomfort.  Specific 
NSAIDs commonly used to treat patients with JIA include acetylsalicylic acid (aspirin), tolmetin, 
naproxen, and ibuprofen, with the last two available as liquids or pills (Ilowite & Laxer, 2010).  
Other NSAIDs include piroxicam (Feldene), nabumetone (Relafen), and celecoxib (Celebrex).  
NSAIDs produce a significant response in approximately 25-33% of patients, many of whom 
have oligoarthritis (Haskes & Laxer, 2005). 
Second-line medications include Disease-Modifying Antirheumatic Drugs (DMARDs), 
corticosteroids, and biological therapies that prevent or decelerate bone and cartilage damage.  
DMARDs are slow-acting medications that take effect after several weeks to months.  
Commonly prescribed DMARDs include methotrexate and sulfasalazine.  Other disease-
modifying drugs include hydroxychloroquine, oral gold, and D-penicillamine.  In contrast, 
corticosteroids are fast-acting, potent, antiinflammatory drugs used to control severe systemic 
symptoms (e.g., fever, rash) or used as bridging medications until slower-acting medications take 
effect (Haskes & Laxer, 2005).  Due to serious adverse effects of prolonged use, corticosteroids 
are typically used acutely or periodically at low dose.  They may be taken orally, through 
intraarticular injection, or through eye drops (Ilowite & Laxer, 2010).  Biological agents are 
recently developed medications and include tumor necrosis factor inhibitors – e.g., adalimumab 
(Humira) and etanercept (Enbrel) – and other classes of drugs.  The tumor necrosis factor 
inhibitors are administered subcutaneously. 
The number of medications, variety of administration routes (oral, injection, topical/eye 
drops), and variety of dosing schedules contribute to the complexity of JIA medication regimens.  
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Characteristics of the JIA medication regimens – their complexity, their delayed effects, their 
adverse side effects, and their chronic necessity – all represent impediments to adherence 
(Rapoff, 2010) that may limit patients’ enjoyment of potential treatment benefits.   
Adherence to JIA Medication Regimens 
 Adherence to medications by pediatric patients with chronic diseases generally averages 
50-55% (Rapoff, 2010).  Estimates obtained through a variety of adherence measures vary for 
patients with chronic arthritis, but they are also generally low.  Litt and Cuskey (1981) found that 
55% of patients with JRA were adherent according to salicylate serum levels.  In other studies, 
38-59% of patients have been classified as adherent according to pill counts or parental 
observations conducted at baseline prior to interventions (Rapoff, Lindsley, & Christophersen, 
1984; Rapoff, Purviance, & Lindsley, 1988a; Rapoff, Purviance, & Lindsley, 1988b).  Electronic 
monitoring has shown that the percentage of primary NSAID doses taken by patients in a control 
group decreased from 73% to 57% over a 52-week period (Rapoff et al., 2002).  Another study 
using electronic monitors found that 52% of patients were fully adherent to a prescribed NSAID 
on more than 80% of days in a 28-day period (Rapoff, Belmont, Lindsley, & Olson, 2005).  
Patients responding to visual analog adherence scales gave mean ratings of 85% for their overall 
medication adherence, and parents gave mean ratings of 83% for their child’s or adolescent’s  
adherence (April, Ehrmann-Feldman, Platt, & Duffy, 2006).  Similarly, parents reported their 
children’s adherence at a mean of 90% (De Civita, Dobkin, Ehrmann-Feldman, Karp, & Duffy, 
2005).  These studies have shown that self-report measures tend to produce higher adherence 
estimates than more objective measures, a pattern observed across studies of pediatric patients 
with a wide range of chronic diseases (Rapoff, 2010).   Because adherence measures vary in their 
metric properties, no gold standard currently exists.  Thus, the use of multiple types of measures 
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is recommended in the assessment of adherence (Quittner, Espelage, Ievers-Landis, & Drotar, 
2000). 
The role of nonadherence among JIA patients is concerning in light of the consequences 
of uncontrolled JIA symptoms (e.g., joint pain and stiffness, joint deformity and loss of 
functionality, disability).  These symptoms may in turn compromise quality of life and interfere 
with patients’ school attendance (Rapoff, 2002).  Feldman and colleagues (2007) reported that 
moderate parent-reported medication adherence levels predicted improvement in subsequent 
active joint counts among JIA patients.  Improving adherence to JIA treatment regimens 
(especially medications) would also allow clinical decisions regarding treatment adjustments to 
be based more on actual treatment effectiveness and would thus maximize the cost-effectiveness 
of the treatments (Rapoff, 2010).  Accurate assessment of potentially modifiable factors that 
could improve adherence would facilitate the targeting of these factors in adherence 
interventions and in the measurement of these interventions’ effects.  Among such factors, 
perceived barriers have demonstrated consistent correlations with health behaviors in the adult 
literature and have been investigated for their relationship with pediatric medical regimen 
adherence.  
Model of Adherence and Perceived Barriers 
 A number of studies have described the associations between pediatric medical regimen 
nonadherence and patient and family, disease, and regimen characteristics (see Rapoff, 2010, for 
a comprehensive review).  Some of these characteristics can be used to identify groups that may 
have more difficulty with adherence (e.g., adolescents, patients from families of lower 
socioeconomic status, patients prescribed more complex medical regimens).  Other correlates 
may be causally related to nonadherence and amenable to modification (e.g., patient’s and family 
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members’ knowledge and beliefs about the patient’s disease and prescribed treatment).  Beliefs 
about treatment have not only represented potentially modifiable factors but also may represent 
stronger predictors of adherence than some patient demographic and regimen characteristics.  A 
study conducted with chronically ill adults found that patient beliefs about medications – 
specifically, the degree to which beliefs about medication necessity were stronger than concerns 
about medications – were more predictive of adherence estimates based on patient self-report 
than were patient age, gender, educational experience, and the number of prescribed medications 
(Horne & Weinman, 1999). 
A well-researched model of patients’ health beliefs and their relationship with health 
behaviors (including adherence), the Health Belief Model was one of the earliest social cognitive 
theories constructed to explain differences in individuals’ health behaviors.  In the 1950s, social 
psychologists in the U.S. Public Health Service initially developed the Health Belief Model to 
understand factors contributing to the lack of participation in preventive health and disease 
detection programs (Strecher, Champion, & Rosenstock, 1997).  The Health Belief Model’s 
focus on potentially modifiable health beliefs allowed this model to provide a theoretical 
framework for designing health education interventions (Abraham & Sheeran, 2005).  The four 
health beliefs originally composing the Health Belief Model were perceived susceptibility to and 
perceived seriousness of a health condition and perceived benefits of and barriers to the 
performance of specific health behaviors.  
As a value-expectancy model, the Health Belief Model identified beliefs related to the 
individual’s perception of personal vulnerability to a health problem, which influenced 
motivation (or state of readiness) to avoid illness or to improve one’s health.  This model also 
identified beliefs related to the individual’s perception of the overall benefit of pursuing a 
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particular health behavior to address this vulnerability (Rosenstock, 1966/2005; Strecher et al., 
1997).  The perceived susceptibility and perceived seriousness components of the Health Belief 
Model composed the perception of personal vulnerability and provided the force propelling 
individuals toward taking action to address this vulnerability.  The perceived benefits and 
perceived barriers of alternative health behaviors contributed to the selection of a specific course 
of action to undertake.  Rosenstock (1966/2005) described perceived susceptibility as the 
individual’s subjective evaluation of risk of contracting a condition.  Perceived seriousness was 
the emotional arousal experienced by the individual when thinking of the health condition and 
the individual’s beliefs about the difficulties resulting from the condition.  He also defined 
perceived benefits of pursuing a specific health behavior as beliefs about the health behavior’s 
availability and efficacy in reducing susceptibility or seriousness of the condition; perceived 
barriers were described as negative aspects of pursuing a health behavior (e.g., inconvenience, 
cost, discomfort).  Later reformulations of the Health Belief Model included additional 
constructs such as cues to action (internal or external cues triggering engagement in health 
behaviors) and Bandura’s concept of self-efficacy (Rosenstock, 2000).   
A pediatric adaptation of the Health Belief Model, the Children’s Health Belief Model 
(Bush & Iannotti, 1990), has been formulated to take into account the influence of parents’ 
beliefs, as well as patients’ beliefs, on patients’ health behaviors.  Previous studies have provided 
mixed evidence regarding the relationship between parents’ health beliefs and patients’ 
adherence to their medical regimens.  Some studies demonstrated a significant relationship (e.g., 
Becker, Radius, Rosenstock, Drachman, Schuberth, & Teets, 1978; Drotar & Bonner, 2009) and 
other studies did not (e.g., Riekert, 2000).  A possible explanation for this inconsistency could be 
that the studies finding nonsignificant relationships may have included more parents of older 
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patients, and thus the parents’ health beliefs would not be expected to be strong predictors of 
adherence because of less direct involvement in supervising their adolescents’ regimens 
(Quittner et al., 2000; Riekert, 2000).  The lack of clarity regarding the relationships among 
patients’ and parents’ health beliefs and the patients’ health behaviors and the likely influence of 
developmental changes on these relationships have highlighted the importance of obtaining 
information from multiple informants when possible. 
Evidence from two quantitative reviews of studies of the four original Health Belief 
Model components demonstrated that the barriers construct was the strongest predictor of health 
behaviors (Abraham & Sheeran, 2005).  Janz and Becker (1984) found that the relationship 
between barriers and health behaviors was significant in the predicted direction in 89% of all 
studies reviewed in which significance levels were presented for barriers.  In 100% of 
prospective studies reviewed, barriers were significantly related to health behaviors in the 
predicted direction.  Harrison and colleagues (1992) found in their meta-analysis that the 
weighted mean correlations between each of the four Health Belief Model components and 
health behaviors had magnitudes ranging from 0.08 to 0.21, with barriers having the strongest 
correlations with health behaviors.  These meta-analyses suggested a consistent, modest 
relationship between barriers and health behaviors, though neither analysis provided a fail safe N 
estimate of the file drawer effect.  However, because of the relationship between barriers and 
adherence reported in the adult Health Belief Model literature, a number of studies with pediatric 
samples have also examined the relationship between patients’ or parents’ perceived barriers and 
medical regimen adherence (e.g., Logan, Zelikovsky, Labay, & Spergel, 2003; Modi & Quittner, 
2006; Simons & Blount, 2007; etc.).  The majority of these studies reported significant, small-to-
moderate relationships between perceived barriers and various measures of adherence.   
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The Health Belief Model was originally used to explain preventive health behaviors.  The 
model has since been applied to explaining behaviors such as adherence to medical regimens 
(Becker, 1974).  Within the context of an established health condition, the Health Belief Model 
components can be understood as acceptance of the condition (perceived susceptibility), health 
and social consequences of not engaging in treatment for the condition (perceived severity), 
perception of the prescribed treatment’s efficacy (perceived benefits), and perception of 
impediments to treatment adherence (perceived barriers) (Rapoff, 2010).  The expansion of the 
barriers construct from perceived negative aspects of the recommended health behaviors to the 
broader category of perceived impediments reflected both the lack of homogeneity in the 
operationalization of the Health Belief Model constructs noted in several reviews of the model 
(Harrison et al., 1992; Rosenstock, 1974) and also the overlap between the barriers construct and 
other Health Belief Model components as well as constructs from other social cognitive theories, 
such as Bandura’s (1977) Social Cognitive Theory and Ajzen and Fishbein’s (1977) Theory of 
Reasoned Action/Theory of Planned Behavior.  For example, a common barrier to adherence, 
forgetting to take medications, reflects a lack of cues to action, while denial of a health condition 
reflects a low level of perceived susceptibility.  
Pediatric Chronic Illness Measures of Barriers to Adherence 
Given the consistent relationship between barriers and health behaviors and the absence 
of well-validated measures of medication adherence barriers designed to assess the experiences 
of JIA patients, the development of such measures may facilitate efforts to improve adherence 
and health outcomes of JIA patients.  Two reviews – one conducted by the author of the first 
version of the Parents Barriers Questionnaire–Juvenile Idiopathic Arthritis and the other 
conducted by this author – of existing barriers measures that have been administered to other 
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pediatric samples provided the basis for developing the JIA barriers measures.  These measures 
included both questionnaires and semi-structured interview protocols that assessed pediatric 
patients’ and their parents’ perception of barriers.  Some of these were primarily measures of 
regimen adherence but included several items or a scale measuring barriers to adherence.  These 
measures have been used to elicit reports from patients as young as eight years of age (Buchanan 
et al., 2012; Farley et al., 2008; Janicke, Storch, Novoa, Silverstein, & Samyn, 2007; Simon, 
Duncan, Janicke, & Wagner, 2012) and have been administered to families with patients having 
a variety of chronic conditions including asthma, cystic fibrosis, epilepsy, human 
immunodeficiency virus (HIV) infection, obstructive sleep apnea, organ transplant recipients and 
candidates, overweight or obesity, chronic pain, and sickle cell disease.  Table 1 summarizes the 
characteristics and psychometric properties reported for the measures reviewed by this author, 
and this review was restricted to measures for which information about psychometric properties 
were reported. 
The information gathered using these measures included qualitative descriptions of 
barriers experienced within a variety of recall periods ranging from the past week to the past 
year, number of barriers endorsed, ratings of the frequencies with which identified barriers were 
experienced (typically on Likert scales with descriptive anchors such as 1 = never and 5 = almost 
always), ratings of the level of difficulty caused by identified barriers, ratings of the level of 
agreement with statements reflecting barriers (typically on Likert scales with anchors such as 1 = 
strongly disagree and 5 = strongly agree), and ranking of the relative importance of the 
identified barriers. 
 Reliability and validity of barriers measures.   Although some of the ways in which 
adherence barriers have been measured in both forced choice questionnaires and open-ended 
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interviews precluded testing certain psychometric properties, evidence of reliability has been 
reported for eleven of the seventeen measures reviewed (Table 1).  Cronbach’s α was reported as 
a measure of internal consistency for nine measures (Buchanan et al., 2012; Logan et al., 2003; 
Modi, Monahan, Daniels, & Glauser, 2010; Simon, Duncan, Janicke, & Wagner, 2012; Simons 
& Blount, 2007), with values ranging from 0.74-0.90.  Test-retest reliability was reported for five 
measures (Logan et al, 2003; Simon et al., 2012; Simons, McCormick, Devine, & Blount, 2010).  
Values ranged from 0.62 to 0.88, and the intervals between administrations ranged from two 
weeks to eighteen months.  
 Evidence of validity was reported for fifteen measures.  Support for the construct validity 
of eleven of these measures included the relationship between the barriers measure and one or 
more measures of adherence.  Most of the barriers measures demonstrated significant 
relationships with adherence in the hypothesized direction.  For a sample of organ transplant 
recipients, Simons and Blount (2007) reported higher mean scale scores on adolescent- and 
parent-report barriers measures for patients classified as nonadherent by their own report and 
parents’ report, respectively, compared to adherent patients (p < 0.05).  However, this 
relationship was not observed when adherence was measured by serum drug levels.  Zelikovsky 
and colleagues (2008) reported moderate correlations between the number of barriers reported by 
adolescent renal transplant candidates and their reported number of missed medication doses (r = 
0.38, p = 0.004) and number of doses taken late (r = 0.47, p < 0.001).  Logan and colleagues 
(2003) reported a moderate negative correlation (r = - 0.35, p < 0.01) between their adolescent-
report barriers measure (scale score) and health care providers’ ratings of patient adherence to 
asthma maintenance medications.  Fisak and colleagues (2012) reported that, in a sample of 
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caregivers of patients with sickle cell disease, caregiver-rated barriers were stronlgy negatively 
correlated with scores from a caregiver-report adherence measure (r = -0.56, p < 0.01).    
In addition to participant- or provider-reported estimates of adherence, other studies have 
used a variety of other measures of adherence as criteria for assessing the validity of the barriers 
measures.  Witherspoon and colleagues (2006) reported that caregiver-rated barriers (reverse 
scored) to their children’s adherence to sickle cell disease treatment correlated strongly with 
adherence estimates derived from pharmacy refill records (r = 0.57, p < 0.01) as well as with 
caregiver-reported adherence estimates (r = 0.66, p < 0.01).  In studies of pediatric patients with 
HIV (Buchanan et al., 2012; Farley et al., 2008; Marhefka, et al., 2006; Marhefka, et al., 2008), 
an increased number of barriers identified by caregivers of these patients was significantly 
related to subjective reports of nonadherence and tended to be associated with detectable viral 
load (p < 0.10). Modi and colleagues (2010) reported the barriers score (reverse scored) of their 
parent-report pediatric epilepsy management measure correlated with adherence measured by 
electronic monitor (r = 0.27, p < 0.01) as well as by parent-reported estimates (r = 0.35, p < 
0.0001).  Similarly, Simon and colleagues (2012) demonstrated that patient- and parent-reported 
barriers ratings were related to electronically monitored use of continuous positive airway 
pressure therapy (r = -0.44, p = 0.002).  However, in a study of barriers reported by patients with 
asthma or cystic fibrosis and by their parents, Modi and Quittner (2006) did not find significant 
correlations between number of barriers reported by parents or patients and a variety of 
adherence measures (parent- or patient-reported, adherence estimated from daily phone diaries, 
pharmacy refill rates, or electronic monitor rates of adherence); correlations with these measures 
ranged from medium-sized correlations in the predicted (negative) direction to medium-sized 
correlations in the opposite (positive) direction. 
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Though concurrent validity was tested for nearly half of the reviewed measures, 
predictive validity was tested for only two. Simons and colleagues (2010) correlated scores from 
the Adolescent Medication Barriers Scale (AMBS) and the Parent Medication Barriers Scale 
(PMBS), administered to adolescent organ transplant recipients and their parents, with adherence 
estimates obtained 18 months later.  Although total scale scores from the AMBS and PMBS did 
not predict adherence, specific barriers demonstrated significant correlations (p < 0.05) with 
adherence (and other clinical outcomes).  Adolescent patients’ scores on the AMBS Disease 
Frustration/Adolescent Issues subscale and on specific items within this subscale – “I sometimes 
just don’t feel like taking the medicine,” “I don’t like what the medication does to my 
appearance,” and “I am tired of taking medicine” – correlated significantly with reports of taking 
doses late at the 18-month follow up (rs = 0.32, 0.39, 0.33, and 0.37, respectively).   Scores on 
the AMBS Disease Frustration/Adolescent Issues subscale and the items “I don’t want to take the 
medicine at school,” “I am tired of taking medicine,” and “I am tired of living with a medical 
condition” also predicted unstable blood levels of the patients’ immunosuppressant drugs at 
follow up (rs  = 0.29, 0.28, 0.37, and 0.34, respectively).  Parents’ scores on the PMBS Regimen 
Adaptation/Cognitive Issues subscale and several of its items – “My child is forgetful and 
doesn’t remember to take his/her medication every time,” “My child is not very organized about 
when and how he/she takes his/her medication,” and “I am not always there to remind my child 
to take his/her medication” – correlated significantly with reports of missed doses at follow up 
(rs = 0.33, 0.37, 0.25, and 0.26, respectively).  Additionally, adolescents whose parents had 
endorsed the barrier, “My child believes the medicine has too many side effects,” were more 
likely to be nonadherent, as indicated by having out-of-range drug levels (point-biserial 
correlation: rpb = 0.32). 
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Barriers commonly endorsed by patients and parents.  To examine the rates at which 
types of barriers were endorsed, this author reviewed 13 studies reporting 17 different measures 
(see Tables 2 and 3 for citations) in which patients or parents were asked to endorse, rate the 
level of difficulty caused by, rate the level of agreement with, or rate the frequency of relevant 
barriers from lists of specific barriers provided in the barriers measure.  Studies in which 
respondents were asked to generate specific barriers in response to open-ended questions were 
excluded unless a list of commonly cited barriers was also provided.  The members of the 
University of Kansas Medical Center (KUMC) Behavioral Pediatrics laboratory derived 16 
categories that represented types of barriers from the items composing the measures of interest 
and then assigned each barrier item to one of the categories.  From published data or data made 
available by the developers of the barriers measures, this author calculated the weighted mean 
percentages of patients and parents sampled who endorsed at least one barrier within each 
category of barriers.   
The ten types of barriers most frequently endorsed by patients across disease groups were 
patient or parent forgetting, disagreement or communication problems with health care 
providers, psychosocial adjustment difficulties, interference between treatment and daily 
activities, difficulties incorporating treatment regimen into daily life, expected or experienced 
treatment side effects, desire to be or to appear to be normal, belief that treatment is not needed, 
regimen complexity, and miscellaneous barriers (e.g., difficulty with equipment related to 
medical treatment).  The ten types of barriers most frequently endorsed by parents were patient 
or parent forgetting, difficulties incorporating treatment regimen into daily life, patients’ dislike 
of medication taste, interference between treatment and daily activities, patients’ oppositional 
behavior or problems with discipline, concerns and misconceptions about medications, expected 
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or experienced treatment side effects, treatment technique or administration difficulty, treatment 
or medication access difficulties, and miscellaneous barriers.  Tables 2 and 3 provide, 
respectively, summaries by disease group of the weighted mean percentages of patients and 
parents who endorsed barriers in the 16 categories.   
Collapsing across disease groups, it was found that the patient and parent lists of most 
commonly identified barriers overlapped (e.g., forgetting and interference between treatment and 
daily activities) but that the two groups also provided non-redundant perspectives (e.g., a greater 
percentage of patients than parents identified disagreement or communication problems with 
health care providers).  Results from studies of patients sharing a particular diagnosis have 
reflected this relationship between patient- and parent-reported barriers as well.  In a study of 
factors influencing adherence in a sample of pediatric patients with asthma, the correlation 
between scores from patient- and parent-rated barriers measures was found to be small but 
significant (r = 0.28, p < 0.05) (Branstetter, 2001).  Other studies of pediatric patients with 
inflammatory bowel disease (Greenley, Stephens, Doughty, Raboin, & Kugathasan 2010), cystic 
fibrosis, asthma (Modi & Quittner, 2006), sickle cell disease (Modi, Crosby, Guilfoyle, 
Lemanek, Witherspoon, & Mitchell, 2009), and renal transplants (Zelikovsky, N., Dobson, T., & 
Norman, J., 2011) found that patients and their parents overlapped in their identification of 
commonly encountered barriers and also identified barriers unique to their perspectives (e.g., 
adolescents more frequently identified desire to be “normal” as a barrier, while parents more 
frequently identified difficulty incorporating certain treatments into their children’s daily lives as 
a barrier).  These findings that patient- and parent-reported barriers provide unique information 
underscore the need to assess both informants’ perceptions systematically and to validate barriers 
measures for patients and parents independently.  
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Study Purpose and Hypotheses 
 Although the Child Adherence Report Questionnaire-Juvenile Idiopathic Arthritis 
(CARQ-JIA) (April et al., 2006) and Parent Adherence Report Questionnaire-Juvenile Idiopathic 
Arthritis (PARQ-JIA) (De Civita et al., 2005) contain items assessing barriers to adherence, test-
retest reliability has only been reported for three of the four PARQ-JIA barriers items and no 
validity testing has been conducted on these items for either measure.  Additionally, the CARQ-
JIA and the PARQ-JIA’s use of a yes/no or checklist response format for the barriers questions 
limits the amount of information elicited about the barriers.  Thus, the purposes of the current 
study were to develop two scales of barriers to adherence, the Barriers Questionnaire-Juvenile 
Idiopathic Arthritis (BQ-JIA) and the Parents’ Barriers Questionnaire-Juvenile Idiopathic 
Arthritis (PBQ-JIA), and to test their psychometric properties.  After conducting a preliminary 
item analysis of the BQ-JIA and PBQ-JIA, this author tested whether these measures elicited 
reliable and valid reports of patient- and parent-perceived barriers that interfere with adherence 
to prescribed JIA medication regimens using a repeated measures study design.  This author 
tested the following hypotheses from the thesis proposal: 
Hypothesis 1: Reliability.  The two barriers measures would demonstrate adequate 
internal consistency (i.e., Cronbach’s α ≥ 0.70) and significant test-retest reliability over a two-
week period.  It was anticipated that, over this brief interval, the experience of adherence barriers 
would be found to be a stable phenomenon.   
Hypothesis 2: Validity.  The two barriers measures would demonstrate adequate 
concurrent, convergent, discriminant, and predictive validities through their relationships with 
measures of related constructs – estimates of medication adherence, reports of general difficulty 
experienced by the patient associated with medication taking, positive and negative outcome 
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expectancies of adhering to the medication regimens, and perceived illness severity and 
susceptibility to illness of the patient.   
Hypothesis 3: Incremental validity.  The two barriers measures would demonstrate 
incremental validity by improving hierarchical regression models’ ability to account for variance 
in adherence when entered after patient demographic, disease, and regimen variables. 
 Hypothesis 4.  Patients with JIA and their parents would provide related yet unique 
perspectives on barriers to adherence.  The expectation was that the scores on the BQ-JIA and 
PBQ-JIA administered concurrently at Time 1 would correlate moderately (i.e., around r = 0.50).  
Also, the most commonly endorsed barriers identified by patients and parents were examined for 
overlapping and non-redundant information.  
 Hypothesis 5.  The relative strengths of the relationships between patient- and parent-
reported barriers and medication adherence estimated by pill count would vary with the patient’s 
age.  Specifically, the prediction was that parent-reported barriers (PBQ-JIA) would be better 
predictors of medication adherence than patient-reported barriers (BQ-JIA) for younger patients, 
and that patient-reported (BQ-JIA) scores would be better predictors of adherence for older 
patients.  
In summary, the aim of the present study was to collect pilot data for refining and 
validating the BQ-JIA and the PBQ-JIA.  These measures may be useful clinical tools for 
assessing perceived difficulties that may prevent medication adherence that patients with JIA and 
their families experience.  Confirming the fourth and fifth hypotheses would lend support for the 
value of assessing patients’ perceptions of adherence barriers as well as those of their parents 
when designing adherence-improvement interventions.   
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Method  
Initial Measure Development 
 A medical student
1
 reviewed four measures of barriers to medical regimen adherence 
(Catz, Kelly, Bogart, Benotsch, & McAuliffe, 2000; Modi et al., 2009; Modi & Quittner, 2006; 
Simons & Blount, 2007) and compiled a list of the items.  These were written to elicit the 
perspective of parents.  He then consulted the KUMC pediatric rheumatologist (who had over 38 
years of experience in the field), the pediatric rheumatology clinic’s nurse (who had over 20 
years of experience), the clinic’s occupational therapist (who had over 25 years of experience), 
and a Ph.D. pediatric psychologist (with over 32 years of experience in pediatric rheumatology), 
asking these experts to indicate independently the items from the list that described barriers to 
medication adherence that were relevant to patients with JIA and their families.  Items that panel 
members independently and unanimously selected were retained, resulting in a thirteen-item 
barriers measure titled the Parents’ Barriers Questionnaire – Juvenile Idiopathic Arthritis (PBQ-
JIA).  The medical student then asked eleven parents of patients with JIA to complete the PBQ-
JIA by endorsing barriers experienced in the past month and to provide feedback regarding 
additional barriers experienced that were not reflected by the measure’s items.  The parents who 
were surveyed endorsed a mean of three barriers (range: 0 – 6).  Individual items were endorsed 
by 0% – 64% of the parents.  The two most commonly endorsed barriers were patient-reported 
bad taste of medication (64%) and the parent’s forgetting to give the medications (45%), and two 
items that were not endorsed by any parents were parent confusion about number of pills of each 
kind of medication to give and parent’s uncertainty about the patient’s need for medication.  
                                                             
1 Scott Matson participated in a month-long research experience (June 2010) as part of his training as a medical 
student at the University of Kansas Medical Center under the supervision of Dr. Carol Lindsley.  
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 The members of the Behavioral Pediatrics laboratory made modifications to the PBQ-
JIA.  Two items were constructed to reflect parents’ feedback on additional barriers experienced 
(“I did not fill or refill my child’s medications because I could not afford it” and “It is hard to fit 
giving my child medications into the family’s routine”) and separated one of the original items 
(“We ran out of the medication or the pharmacy ran out”) into two distinct items for greater 
clarity (“We ran out of medication” and “The pharmacy ran out of medication”).  Five items 
proposed for inclusion in the measure based on this author’s review of the barriers measures 
literature were reviewed by the original panel of experts to determine relevance to the JIA 
population.  The experts were again asked to rate the potential items independently, though the 
pediatric rheumatologist and occupational therapist may have consulted with each other because 
of the close nature of their working relationship.  These last five proposed additions to the PBQ-
JIA represented barriers categories (see Tables 2 and 3) that the original items did not reflect, or 
they captured broader aspects of other, more specific items.  The consulted experts unanimously 
selected two items (“My child does not like the medications’ side effects” and “My child does 
not understand why he/she needs to take the medications when he/she is feeling well”).  The 
number of items in the PBQ-JIA then stood at 18.  
 In addition to increasing the number of items, this author modified the questionnaire’s 
response format.  This author wrote new instructions to direct respondents to identify all barriers 
to medication adherence ever experienced and to report how frequently each barrier was 
experienced in the past seven days.  The frequency ratings were made on a three-point Likert 
scale with qualitative anchors of 0 = never, 1 = sometimes, and 2 = often.  These changes were 
intended to support comparisons of the relationship between total number of barriers and 
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medication adherence to the relationship between the frequency of experiencing barriers and 
medication adherence.   
This author also rewrote the measure’s items and instructions to address the patient’s 
experience of barriers to his or her own medication adherence, creating a corresponding patient 
version of the PBQ-JIA called the Barriers Questionnaire – Juvenile Idiopathic Arthritis (BQ-
JIA).  See Appendix A for copies of the PBQ-JIA and BQ-JIA. The BQ-JIA has a Flesch 
Reading Ease level of 72.4 and a Flesch-Kincaid Grade Level of 7.0 (Flesch, 1948; Kincaid, 
Fishburne, Rogers, & Chissom, 1975), indicating that the measure requires at least a seventh-
grade reading level. When the word “medication,” a word with which young patients with 
chronic illnesses are likely to be more familiar than healthy peers, was removed, the Flesch 
Reading Ease level was 80.6 and the Flesch-Kincaid Grade Level was 5.8, indicating that a fifth-
grade reading level may be sufficient for understanding the measure.   
Participants 
 Participants in this study were recruited from among the patients treated in the clinic of 
the Pediatric Rheumatology Division at an academic medical center in a Midwestern city as well 
as several outreach clinics.  Families meeting the following inclusion criteria were recruited for 
this study: (a) at least one of the children had received a JIA diagnosis from a pediatric 
rheumatologist according to established criteria (Fink, 1995); (b) the patient with JIA was 
between 11.00 and 18.99 years of age; (c) the patient was prescribed at least one medication to 
be taken at least once daily as part of treatment for JIA throughout the duration of their study 
participation; and (d) one of the patient’s parents or caretakers also consented to participate in 
the study.  Although barriers to adherence have been shown to affect younger patients with 
chronic illnesses as well as older children and adolescents, recruitment for this study targeted 
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patients in the 11-18 age range as a starting point, with the intention of investigating barriers in 
younger patients in future studies. 
Exclusion criteria were as follows: (a) parent-reported developmental delays in the 
patient with JIA; (b) patient had a psychiatric diagnosis; (c) the family was non-English 
speaking; (d) the family did not have reliable access to a phone; or (e) the family was receiving 
services or interventions intended to improve medical regimen adherence.  Because translated 
versions of most of the study measures were not available, and the phone interviewer primarily 
spoke English, families who did not speak English were not recruited.  Also, one of the study’s 
purposes was to establish the temporal stability of the two barriers measures over a period of two 
weeks, so patients whose adherence behaviors and barriers were being targeted for modification 
could not be recruited.    
Measures 
 Background information about participating families and information regarding the 
patient’s JIA diagnosis and treatment regimen were gathered from a Participant Demographics 
Form, a brief interview with the participating parent, and a review of the patient’s medical chart.  
To determine the convergent validity of the BQ-JIA and the PBQ-JIA, this author measured 
related health beliefs and global estimates of medication-taking difficulty.  To determine 
concurrent validity and predictive validity, this author measured medication adherence using two 
methods, self-reported estimates and pill counts, in accordance with the recommendation to use 
multiple assessments of adherence because no gold standard has been established (Drotar, 
Richard, Burgess, Levi, Nobile, Seti, & Walders, 2000).   
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Measures of demographic variables. 
Participant Demographics Form (Appendix B).  This form was used to collect 
information from parents about themselves and their children with JIA including the patient’s 
gender, date of birth, age at time of JIA diagnosis, and ethnicity; parent’s relationship to patient, 
age, marital status, occupation, and completed education level; number of siblings with and 
without chronic illness, household composition, and family income.   
Hollingshead Index (HI) (Hollingshead, 1975), Revised Form (HRF) (Wasser, 1992) 
(Appendix C).  From the socioeconomic information provided by parents, this author determined 
the HI of each family based on the completed education level and current occupation of each 
gainfully employed parent (Hollingshead, 1975).  According to the HRF instructions (Wasser, 
1992), education level was scored on a 4-point scale and occupation was scored on a 9-point 
scale that categorized the 450 occupational titles and codes from the 1970 US Census.  This 
author calculated each family’s HI as the sum of the individual, employed parents’ HI scores, 
which were the sum of each person’s education scale score weighted by 3 and occupation score 
weighted by 5. 
Although the HI has been identified as the most frequently used index of socioeconomic 
status, Ensminger and Fothergill (2003) have recommended the examination of specific 
socioeconomic status-related variables individually as well as composite scores to determine 
which best predict other criterion measures.  Both the HI (r = 0.31, p = 0.07) and the household 
annual income (r = 0.31, p = 0.08) were found to be predictors of pill count adherence at a trend 
level of significance, and they were therefore included in the hierarchical regression model used 
to test the incremental validity of the BQ-JIA.  
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 Measures of medical regimen variables. 
Parent  interview (Appendix D).  This author asked participating parents to give the 
name, dose amount, dosing frequency, and form (pill, liquid, or injection) of each medication 
prescribed for their children’s JIA treatment.  This author also asked parents to report any recent 
changes in the prescribed regimen.   
Medical chart review.  This author reviewed each participating patient’s medical chart to 
confirm the patient’s age at the time of diagnosis, specific JIA diagnosis, currently prescribed 
medications and dosing information, and current level of symptom severity (indicated by the 
active joint count, which is the number of joints with active inflammation).  This author also 
recorded specific medication names and their form and class (NSAID, DMARD, corticosteroids, 
biological agents). 
 Medication Regimen Complexity Index (MRCI) (George, Phun, Bailey, Kong, & 
Stewart, 2004) (Appendix E).  From the information gathered through the parent interview and 
the medical chart reviews, this author calculated the MRCI, a score summarizing regimen 
complexity that takes into account the dosage form (e.g., liquids, eye drops, injections), dosing 
frequency, and additional directions included in prescriptions for each medication.  Time to 
calculate the MRCI for each regimen depended on level of complexity.  George and colleagues 
(2004) demonstrated the MRCI’s criterion validity by correlating its ranking of theoretical 
medication regimens with an expert panel’s rankings.  The authors also demonstrated high 
interrater and test-retest reliabilities for the MRCI total score and its individual section scores. 
In their review of medication regimen factors’ influence on treatment adherence, 
Ingersoll and Cohen (2008) found that medication regimen factors have typically been measured 
and analyzed individually, with dose frequency demonstrating an important relationship with 
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adherence.  Few composite scores operationalizing “medication regimen complexity” have been 
used, but Ingersoll and Cohen recommended the incorporation of such indices in studies of 
adherence.  Because the MRCI has not been used in many studies of adherence to pediatric 
chronic illness regimens, and one of these studies did not find a significant relationship between 
the MRCI and self-reported medication adherence (Dean, Wragg, Draper, & McDermott, 2011), 
this author measured and tested the relationships between adherence and the individual regimen-
related variables (e.g., number of medications, highest and lowest dosing frequencies, forms of 
medications) as well as the MRCI scores.  None of the individual variables were found to predict 
adherence at a trend level (all ps ≥ 0.23), though the MRCI scores did (r = 0.27, p = 0.12).  The 
MRCI scores were thus entered as a predictor in the hierarchical regression model testing the 
BQ-JIA’s incremental validity. 
Measures of adherence and other validation criteria.  Because of the different 
strengths and weaknesses of various adherence measures, no single measure is generally 
regarded as the gold standard.  Instead, the recommendation has been to assess adherence using 
multiple methods of assessment, e.g., complementing a self-report measure with a more 
objective measure (Drotar et al., 2000; Quittner et al., 2000).  In this study, we used pill counts as 
the more objective measure in addition to self-report measures to obtain patients’ and parents’ 
estimates of medication adherence.  Pill count adherence rates were calculated as the total 
number of doses taken within the pill count interval divided by the total number of doses 
prescribed for all medications within a medication category (e.g., all NSAIDs prescribed for a 
patient).  In analyses involving measures of adherence rates and barriers to adherence at Time 1, 
the self-report measures served as the adherence measures.  In analyses involving measures of 
adherence at Time 2, the pill count adherence rates were used as the primary adherence measure 
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because of their less subjective nature and because fewer pill count adherence values were 
imputed compared to parent- and patient-reported adherence estimates.  Though the patient- and 
parent-reported adherence estimates at Time 2 demonstrated moderate positive correlations with 
pill count estimates of adherence (r = 0.371, p = 0.04; r = 0.456, p = 0.009; respectively), 
secondary analyses were conducted using  participant-reported adherence rates so that both the 
relationship between barriers and objectively measured adherence and the relationship between 
barriers and families’ perceived adherence could be examined.     
Pill Count.  This author asked the parents to count the number of pills, to report the 
percentage of the volume of liquid medication remaining, or to report the number of syringes 
remaining for each medication.  Because patients stored medications in multiple containers (e.g., 
the supply of naproxen was divided between a bottle stored at home and a bottle stored in the 
patient’s book bag, or a week’s supply of hydroxychloroquine was stored in a pill-reminder 
container at the beginning of each week), this author asked parents about all the containers used 
to store the patients’ medications and prompted the parents to report the total number of pills (or 
the total volume or the number of syringes) for each medication to improve the accuracy of the 
adherence estimates (Rapoff, 2010).  The first and second pill counts were scheduled 
approximately two weeks apart, though the actual interval ranged from 10 to 62 days with the 
median pill count interval equaling 14 days (M(SD) = 16 (8)). Both pill counts were conducted 
over the phone with the participating parent, except in one case in which the pill count was 
conducted with the adolescent patient.  Pill count adherence estimates were restricted to 0-100%, 
so that the effect of error due to medication dumping would be limited.  Adherence estimates for 
each NSAID, DMARD, CS, and biological agent that was not prescribed p.r.n. were calculated. 
The weighted mean of these estimates served as the single estimate of overall medication 
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adherence by pill count, as pill count estimates of adherence did not appear to vary 
systematically by type of medication (F(3, 71) = 0.441, p = 0.724).  Although pill counts do not 
confirm ingestion of medications and may overestimate adherence compared to blood assays 
(Rapoff, 2010), we chose to assess adherence through pill counts because of their feasibility, 
minimal invasiveness, and ability to provide adherence estimates for multiple medications.  
Child Adherence Report Questionnaire – Juvenile Idiopathic Arthritis (CARQ-JIA) 
(April et al., 2006) and Parent Adherence Report Questionnaire – Juvenile Idiopathic Arthritis 
(PARQ-JIA) (De Civita et al., 2005) (Appendix F).  The CARQ-JIA and the PARQ-JIA were 
developed to assess the patient’s and parent’s perceptions, respectively, of the distribution of 
treatment responsibilities among family members, the patient’s ability to follow treatment 
recommendations, errors in taking medication, and the helpfulness of different regimen 
components.  The PARQ-JIA included an additional item with a checklist of potentially 
problematic issues that could affect the patient’s treatment.  The two measures used a series of 
visual analog scales (VAS) to assess the patient’s ability to follow each of three treatment 
recommendations – medications, prescribed exercises, and wearing splints – as they were 
relevant to the individual patient.  The first item asked the respondent to rate the difficulty with 
which the patient followed each of the three treatment recommendations by drawing a line on the 
corresponding 100 mm VAS with endpoint anchors of very easy and very hard.  The second item 
asked the respondent to rate the patient’s frequency of following the three recommendations on 
the corresponding VAS with endpoint anchors of never and always.  The third item asked the 
respondent to rate the frequency of the patient’s negative reactions to the three treatment 
recommendations on the corresponding VAS with endpoint anchors of never and always.  Child 
ability scores for taking medications, performing exercises, and wearing splints were the means 
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of the three VAS items corresponding to these different treatments calculated with first and third 
items reverse-scored.  
De Civita et al. (2005) provided the following evidence for the reliability and validity of 
the PARQ-JIA’s VAS items assessing the patient’s ability to adhere to medication 
recommendations.  The first and second VAS items demonstrated moderate concordance over 
time (intraclass correlation coefficient, ICC = 0.62 and ICC = 0.60, respectively).  The third 
VAS item demonstrated poor concordance over time (ICC = 0.38).   Moderate relationships with 
parent-reported global estimates of adherence (r = 0.38, p = 0.033) and adherence estimates 
calculated from parent-completed treatment adherence diaries (kappa = 0.40) provided evidence 
for the validity of the PARQ-JIA’s child ability score for medications.  From administering the 
CARQ-JIA to a sample of patients (age 9-18 years old) and administering the PARQ-JIA to their 
parents, April et al. (2006) found fair parent-patient agreement on estimates of adherence to 
medications (ICC = 0.32) and difficulty taking medications (ICC = 0.33), demonstrating that the 
CARQ-JIA can be used to elicit estimates of overall adherence to medication regimens from 
pediatric patients. 
In the present study, two of the child ability-medication items from the CARQ-JIA were 
used to help establish the validity of the BQ-JIA.  The general level of difficulty VAS item 
(designated CARQ1) provided a criterion for establishing convergent validity of the BQ-JIA’s 
scale score, and the frequency of following recommendations item (CARQ2) provided a global 
estimate of medication adherence, which was used to test the concurrent and predictive validities 
of the barriers measure.  We used the corresponding items from the PARQ-JIA (designated 
PARQ1 and PARQ2) to help establish the validity of the PBQ-JIA.  To make the PARQ-JIA 
items consistent with the CARQ-JIA items, this author modified the original stems of the two 
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PARQ-JIA items so that the recall period would be the past week instead of the past three 
months.  Shortening the recall period of the PARQ-JIA items to a one-week period was also 
intended to increase response accuracy (Rudd, 1993).  Responses to each of the VAS items were 
recorded as the percentage of the scale length to the left of the line drawn by the respondent.  The 
data collected from the present study’s sample indicated that the test-retest reliability of the 
CARQ-JIA and the PARQ-JIA VAS items was supported; the test-retest correlation coefficients 
ranged from r = 0.422 to r = 0.533 (ps all < 0.05).  This suggested that general difficulty with 
medication adherence as well as participant-reported adherence were somewhat stable through 
the duration of this study, which was consistent with the expectation that these constructs would 
be stable over a short time period in the absence of an intervention targeting adherence.  
Beliefs About Medication Scale (BAMS) (Riekert, 2000; Riekert & Drotar, 2002) 
(Appendix G).  The BAMS was a 59-item questionnaire designed to assess health beliefs that 
affect a patient’s adherence to a chronic illness treatment regimen involving medication.  
Adolescent (ages 11-18 years old) and mother versions were developed to measure both patients’ 
and parents’ beliefs.  The four BAMS subscales were Perceived Threat (PT, a combination of the 
respondent’s perception of the patient’s illness severity and susceptibility to illness), Positive 
Outcome Expectancy (POE, beliefs about the benefits of adhering to the prescribed medication 
regimen), Negative Outcome Expectancy (NOE, beliefs that present barriers to medical 
adherence and beliefs about negative consequences of engaging in adherence behaviors), and 
Intent to perform adherence-related behaviors in the next two weeks.  To complete the measure, 
respondents would rate their level of agreement with health belief statements on a 7-point Likert 
scale having endpoint anchors of strongly disagree and strongly agree for items measuring the 
PT, POE, and NOE constructs or having endpoint anchors of definitely not likely and definitely 
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likely for items measuring Intent.  The PT, POE, NOE, and Intent subscales have demonstrated 
acceptable internal consistency (Cronbach’s α of 0.80, 0.87, 0.86, and 0.79, respectively) and 
test-retest reliability (0.72, 0.77, 0.75, and 0.71) for a sample of patients with asthma, HIV, or 
inflammatory bowel disease over a period of three weeks.  The BAMS-Adolescent Version and 
its subscales have also demonstrated adequate validity, accounting for a significant portion of 
variance in medication adherence above and beyond that accounted for by demographic and 
illness variables (Riekert & Drotar, 2002).  The BAMS-Mother Version subscales also 
demonstrated acceptable internal consistency (Cronbach’s α values of 0.81 for PT, 0.76 for POE, 
and 0.77 for NOE) and test-retest reliability (0.89, 0.83, and 0.69, respectively), but the 
relationship between the subscale scores and adherence was nonsignificant (Riekert, 2000).   
In the present study, patients and parents independently completed modified forms of the 
BAMS-Adolescent Version and BAMS-Mother Version that did not include the seven Intent 
items.  These modified forms were designated BAMS-Patient and BAMS-Parent.  Data from the 
present study’s sample of patients with JIA and their parents indicated that all subscales of the 
BAMS demonstrated degrees of internal consistency comparable to those previously reported by 
Riekert and Drotar (BAMS-Patient subscales (Cronbach’s α): PT (0.81), POE (0.86), and NOE 
(0.85); BAMS-Parent subscales: PT (0.87), POE (0.76), and NOE (0.80)).  Correlations between 
the BAMS-Patient’s three subscales and the BQ-JIA and between the BAMS-Parent’s three 
subscales and the PBQ-JIA administered at Time 1 were used to test the convergent and 
discriminant validities of the BQ-JIA and PBQ-JIA, because the BAMS NOE subscale measured 
a construct related to barriers while the PT and POE subscales measured constructs related to but 
distinct from barriers.  Measuring Intent to engage in adherence behaviors was not necessary 
because medication adherence was measured directly in this study.   
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Procedure 
 Recruitment.  We obtained approval from the Institutional Review Board at the KUMC.  
The education coordinator of the KUMC pediatric rheumatology clinic and the occupational 
therapist assisted this author in identifying patient families who met the first three inclusion 
criteria and the next clinic appointments that these families had scheduled.  The education 
coordinator and occupational therapist also assisted this author with recruiting families for the 
study.  At the end of an eligible patient’s clinic visit, the education coordinator or the 
occupational therapist (recruiter) confirmed that the patient met the other inclusion criteria and 
were not deemed ineligible due to exclusion criteria.  The recruiter then provided a flier with a 
brief description of the study’s purpose and procedures and sought the family’s permission for 
this author to meet with them in person or contact them by phone to give more information about 
the study and to facilitate informed consent.  Interested families were provided a packet that 
included consent and assent forms, four sets of questionnaires, and pre-stamped and addressed 
return envelopes. 
Per informed consent procedures, this author reviewed the patient assent form and the 
parent consent form (which was used to obtain the parent’s consent to participate as well as the 
medical records release authorization) with the family, answered any questions the family had, 
and provided the family with copies of the signed forms if the family chose to participate.   
Patients who were 18 years of age were provided an adult-participant consent form in place of 
the assent form.  When this author was unable to be present at the pediatric rheumatology clinic 
and outreach clinics, consent was obtained by three-way conference call with the patient and 
participating parent, another researcher (who served as a witness), and this author.  Families who 
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agreed to participate mailed signed consent and assent forms to the KUMC Behavioral Pediatrics 
laboratory using an envelope provided with the study materials.  
Study procedure.  When the patient assent and parent consent forms were signed in the 
clinic, a telephone interview with the parent was scheduled within the next 48 hours.  When the 
consent procedure was conducted over the telephone, the interview followed the signing of the 
forms.  During this interview, information about the parent’s understanding of the patient’s 
medication regimen and the first set of pill counts were obtained.  After the first pill count, this 
author prompted both participants to complete the Time 1 questionnaires independently and to 
mail them to the laboratory in a second envelope given to them.  The Time 1 questionnaires 
included the demographics form, the BQ-JIA and PBQ-JIA, two items from the CARQ-JIA and 
PARQ-JIA, and the modified versions of the BAMS (Patient and Parent forms).  Completion of 
study measures at Time 1 was expected to take 25-35 minutes.  The Time 2 pill count interview 
was scheduled with the parent approximately two weeks after the first.   
Between Time 1 and Time 2, this author reviewed the patient’s medical chart and 
consulted with the clinic nurse or occupational therapist when discrepancies arose between the 
parent’s description of the medication regimen and the regimen recorded in the medical record.  
The clinic nurse or this author called the patient’s parent to help clarify their understanding of the 
patient’s prescribed regimen.   
During the Time 2 phone interview, this author asked the parent about any changes in the 
prescribed regimen made during the intervening time and completed the second pill count with 
the parent.  This author then prompted the participants to complete the second set of study 
measures and to mail them back to the laboratory using the provided envelope.  The Time 2 
questionnaires were the BQ-JIA and PBQ-JIA and the two items from the CARQ-JIA the 
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PARQ-JIA.  Completion of the Time 2 questionnaires and the pill count was expected to take 10-
15 minutes. 
A family’s participation was completed when this author had received the completed 
Time 1 and Time 2 questionnaires and had extracted the relevant information from the patient’s 
medical charts.  The Behavioral Pediatrics laboratory mailed a thank-you card to the family.  
This author calculated the HI based on information in the Demographics Form and the MRCI 
based on the review of the patient’s chart and the parent interview. 
Statistical Analyses 
 Data analyses were conducted using IBM SPSS version 18.  All data were re-entered 
after data collection was complete, and discrepancies between the original dataset and the re-
entered dataset were resolved to ensure correct data entry.  Two-tailed tests of significance were 
conducted, and the level of significance was set at 0.05 for all analyses with the exception of 
analyses used to identify demographic, disease-related, and regimen-related predictors of 
adherence that were entered in a hierarchical regression model (level of significance was set at 
0.20).  After preliminary analyses of the data obtained through the different measures, a series of 
bivariate correlations, hierarchical regression, and polynomial regression analyses were 
conducted to refine the BQ-JIA and PBQ-JIA and to test the study’s hypotheses. 
Missing data. 
 This author attempted to minimize missing data by checking all measures when they 
were returned to the laboratory and contacting participants if data were missing and could 
reasonably be recovered.  Roughly 45% of the originally missing data were recovered in this 
way.  Of the 35 participating families, nine had missing responses that were not recovered.  Two 
of these families did not return any Time 2 questionnaires, one did not return the patient’s Time 
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2 questionnaires, and the remaining six families were missing responses to one or two 
questionnaire items from Time 1 or Time 2, but these responses could not be recovered.  The 
unrecovered missing data were found on 30% of variables and, in total, accounted for 2.1% of all 
values in the dataset.  Using SPSS procedures, this author found that Little’s Missing Completely 
At Random test was significant (χ2(1569) = 6.14 E 26, p < 0.001).  This indicated that the 
mechanism of missingness was not Missing Completely At Random.  It was assumed that the 
data were Missing At Random – that is, that missingness was not related to the underlying values 
of the missing data but to other measured variables included in the analysis.  The assumption of a 
Missing At Random mechanism was supported for missing values on the Time 2 questionnaires 
that were not returned: independent samples t tests comparing cases with missing values and 
cases without missing values on the Time 2 questionnaires indicated that these two groups did 
not differ significantly on the Time 1 questionnaires that were also administered at Time 2 (ps all 
> 0.05), suggesting that the missing values on Time 2 questionnaires likely did not differ 
significantly from the values collected from the other participants.  The assumption of a Missing 
At Random mechanism for missing values on individual variables derived from Time 1 
questionnaires could not be tested empirically, and it is acknowledged that a missing not at 
random mechanism could plausibly underlie the missing values on these variables (e.g., missing 
responses to the household annual income item of the demographics questionnaire could be 
related to the these families’ unreported income level).   
SPSS multiple imputation was used to estimate missing values in accordance with 
Tabachnick and Fidell’s (1996) recommendations.  Multiple imputation was selected for the 
purpose of obtaining more reliable parameter estimates from statistical analyses conducted on 
these imputed datasets compared with parameter estimates following traditional methods of 
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addressing missing data (e.g., deletion and single imputation) (Baraldi & Enders, 2010). Twenty 
imputations were conducted per the rule of thumb given by Graham and colleagues (2007).  
Variables for which values were imputed were originally missing 2.9% to 11.4% of values.  
Reported results of statistical analyses were pooled parameter estimates derived from SPSS 
multiple imputation procedures or from calculation of the mean of parameter estimates from 
each of the imputed datasets.  However, descriptive statistics summarizing sample demographics 
were calculated on the original dataset with numbers of cases with missing values being reported 
separately.  
Results 
Study Sample 
The CONSORT diagram (Figure 1) summarized screening, recruitment, and attrition.  A 
total of 596 patients were pre-screened for study eligibility by clinic personnel’s review of 
medical charts.  The majority (487 patients, 81.7%) were deemed ineligible; of the 109 
remaining, 31 (28.4%) were missed during their clinic visit(s), nine (8.3%) declined study 
participation due to lack of interest or time, seven (6.4%) were not recommended for study 
participation by the treating physician, and two families (1.8%) did not wish to participate 
because they were moving out-of-state.  Of the 60 families who reported interest in the study and 
gave permission for this author to contact them with additional information, 46 (76.7%) families 
enrolled in the study; the other 14 families were lost to follow up (did not respond to calls 
regarding scheduling a time to review consent forms).  Two of the enrolled families were later 
excluded from analyses because the diagnosis had been incorrectly recorded, and the patients had 
not been diagnosed with JIA.  Of the 44 remaining families, nine (20.5%) did not complete Time 
1 measures: eight of these were lost to follow-up (did not respond to three phone calls and a 
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mailed letter from the researchers), and one family discontinued participation due to acute 
worsening of the patient’s symptoms and lack of time.  Of the 35 families who completed the 
Time 1 measures, three (8.6%) did not complete the Time 2 measures: two of these were lost to 
follow-up (one returned the Time 2 parent-report questionnaires but not the patient-report 
questionnaires) and one family reported loss of interest in the study.   
The 26 families who were eligible and were approached regarding the study but either did 
not consent to participate or did not complete the entire study were compared with the 32 
families who completed the study.  Patients in these two groups did not differ significantly with 
respect to whether families were recruited at KUMC or at an outreach clinic (recruited at 
KUMC: 35% of non-completers, 34% of completers; χ
2
(1) < 0.001, p = 0.99), proportion of 
female patients (92% of non-completers, 88% of completers; χ
2
(1) = 0.36, p = 0.55), age of 
patients at time of consent or recruitment (M (SD): 15.04 (2.01) years for non-completers, 14.93 
(2.20) years for completers; t(56) = -0.20, p = 0.84), or JIA subtype (χ
2
(5) = 2.71, p = 0.74).  
Though information about medication adherence or disease severity was not available for non-
completers, these findings suggested that the study sample was somewhat representative of the 
population of 11 through 18 year-old patients with JIA from whom they were recruited.  See 
Table 4 for a summary of the characteristics of non-completers and completers. 
Table 5 summarized the demographic and medical characteristics of the 35 families who 
completed at least the Time 1 measures.  Roughly two thirds of participants were recruited 
through the pediatric rheumatology outreach clinics.  The majority of patients were female 
(86%), Caucasian (71%), specifically diagnosed with RF-negative polyarthritis (51%), and had 
one or more joints actively affected by the disease (60%).  Patients ranged in age from 11.2 years 
to 18.2 years at the beginning of the study (M(SD) = 15.0 (2.2) years).  All patients’ medical 
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regimens included at least one NSAID, 86% of patients were prescribed at least one DMARD, 
and a small minority were prescribed a corticosteroid (17%) or a biological agent (17%).  The 
median number of medications prescribed to treat JIA symptoms was three.  This did not include 
supplements that may have also been recommended.  The majority of patients lived in two-
parent households (83%), and 89% of adult participants were the patients’ mothers.  The parents 
participating in this study tended to be well-educated (i.e., achieved post-secondary education 
degrees), and over half reported annual household income of $50,000-$75,000 or $75,000-
$100,000. 
Mean participant-reported (at Times 1 and 2) and pill count (Time 2) adherence ranged 
from 0.78 to 0.84, suggesting that patients were generally adherent to their medication regimens.  
At Time 1, 71% of parents and 66% of patients reported at least an 80% adherence rate.  At Time 
2, 61% of parents and 72% of patients reported at least an 80% adherence rate.  According to pill 
counts, 68% of patients took at least 80% of the prescribed doses of medications during the study 
period.  Bivariate correlations among the three adherence measures taken at Time 2 suggested 
convergence across the subjective and objective measures of adherence.  Patient- and parent-
reported adherence rates demonstrated strong, positive correlations at both Time 1 (r = 0.534,     
p = 0.001) and Time 2 (r = 0.518, p = 0.004).  Participant-reported adherence rates obtained at 
Time 2 demonstrated moderate, positive correlations with pill count weighted mean adherence 
rates (r = 0.371, p = 0.04 and r = 0.456, p = 0.009 for patient- and parent-reported rates, 
respectively). 
Item Analysis   
As part of refining the BQ-JIA and PBQ-JIA, this author identified individual items that 
might detract from the measures’ utility.  First, this author examined the distribution of 
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frequency responses to each item and found that the distributions of responses to over a third of 
the items in the BQ-JIA and over half of the items in the PBQ-JIA were significantly skewed.  
Second, this author found that two thirds of the items in the BQ-JIA and a third of items in the 
PBQ-JIA demonstrated low item-total correlations (i.e., r < 0.25).  Third, this author found that 
over one third of BQ-JIA items and over two thirds of the PBQ-JIA items were highly correlated 
with other items (r > 0.5).  Items that exhibited all three of the above characteristics (i.e., items 3, 
5, and 12 on the BQ-JIA; item 15 on the PBQ-JIA) were considered for elimination, though 
decisions about eliminating items would be better informed by a study with a larger group of 
participants.  The distributions of item responses obtained from a larger sample would more 
reliably reflect item response distributions in the population, and a larger sample size would also 
support an exploratory factor analysis to facilitate exploration of the structures of the measures.  
Though the determination of an adequate sample size for an exploratory factor analysis varies 
depending on the magnitude of communalities, number of factors, and number of indicators per 
factor, application of an EFA to the BQ-JIA or PBQ-JIA would likely require a sample size 
greater than 100, assuming the communalities would be moderately large given the measures’ 
likely low indicator to factor ratio (MacCallum, Widaman, Zhang, & Hong, 1999). At this point, 
all items on both barriers measures were retained. 
Testing Hypothesis 1: Prediction of Significant Internal Consistency and Test-retest 
Reliability of the BQ-JIA and PBQ-JIA     
Tests of internal consistency were conducted on patients’ and parents’ ratings of barrier 
frequencies on the BQ-JIA and the PBQ-JIA at Time 1.  Internal consistency was low for the 
BQ-JIA (Cronbach’s α = 0.41), suggesting the need for item reduction in a future, larger study.  
The PBQ-JIA, however, demonstrated adequate internal consistency (Cronbach’s α = 0.72).   
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The test-retest reliability of the two barriers measures was assessed by correlating Time 1 
and Time 2 measure outputs – number of barriers ever encountered, number of barriers 
encountered in the past week, and barriers measure total score based on frequencies of barriers 
encountered in the past week.  The BQ-JIA demonstrated adequate test-retest reliability (rs 
ranged from 0.55 to 0.56, all ps = 0.001), and the median test-retest interval was 19 days 
(M(S.E.) = 27 (3.4); range: 12-93 days).  When test-retest reliability correlations were compared 
between patients whose test-retest interval was equal to or shorter than the median interval and 
patients whose test-retest interval was longer than the median interval, it was found that the 
correlations were not significant for the latter group (rs ranged from 0.40 to 0.46, all ps ≥ 0.09).  
This comparison indicated that test-retest reliability of the BQ-JIA was better supported (rs 
ranged from 0.62 to 0.67, all ps ≤ 0.004) over shorter intervals (i.e., 19 or fewer days).  The 
PBQ-JIA demonstrated adequate test-retest reliability (rs ranged from 0.74 to 0.78, all ps < 
0.001), and the median test-retest interval was 19 days (M(S.E.) = 27 (3.2); range: 11-88 days).  
The test-retest reliability of the PBQ-JIA was supported over the range of test-retest intervals.       
Testing Hypothesis 2: Prediction of Adequate Concurrent, Convergent, Discriminant, and 
Predictive Validities 
The concurrent, convergent, discriminant, and predictive validities of the BQ-JIA and the 
PBQ-JIA were determined by examining the relationships between each measure’s output (Time 
1) with the other measures completed by the same participant (patient or parent) at Time 1 and 
Time 2 as well as pill count adherence.  Correlations among patient-report measures and 
correlations among parent-report measures were summarized in Tables 6 and 7, respectively.  
Table 8 provided a summary of mean patient- and parent-scores on study measures, as well as t 
tests and correlations comparing these sets of scores. 
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Concurrent validity.   
Concurrent validity was determined through correlating the output from the BQ-JIA with 
the patient-reported adherence estimate (CARQ2).  The sum of the frequency scores for barriers 
experienced in the past week exhibited the strongest correlation with patient-reported adherence 
(r = -0.403, p = 0.02).  Of the PBQ-JIA outputs, the number of parent-reported barriers 
experienced in the past week was most strongly correlated with parent-report adherence (r =        
-0.555, p < 0.001).  The sum of frequency scores served as the BQ-JIA output variable in 
subsequent analyses of the measures’ convergent and discriminant validity, and the number of 
barriers experienced in the past week served as the output variable for the PBQ-JIA. The 
moderate-to-strong, negative correlations between the barriers and adherence measures were 
consistent with the Health Belief Model’s prediction of the relationships between the constructs 
they measure, lending support for the concurrent validity of the barriers measures.  
Convergent validity and discriminant validity.   
Convergent validity of the BQ-JIA and PBQ-JIA was assessed through correlating the 
barriers measures’ output with the CARQ1 and PARQ1 items measuring general level of 
difficulty (Time 1) and the Negative Outcomes Expectancy (NOE) subscale scores from the 
BAMS measures.  The BQ-JIA exhibited a moderate, positive correlation with the CARQ1 (r = 
0.466, p = 0.004) and a strong, positive correlation with the NOE subscale from the BAMS-
Patient (r = 0.640, p < 0.001).  Similarly, the PBQ-JIA correlated strongly and positively with 
both the PARQ1 (r = 0.519, p = 0.001) and the NOE subscale from the BAMS-Parent (r = 0.491, 
p = 0.002).  These moderate-to-strong, positive correlations between the barriers measures and 
previously established measures of related constructs supported the convergent validity of the 
barriers measures. 
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Divergent validity of the barriers measures was assessed through the comparison of 
correlations between the barriers scales’ output variables and the Perceived Threat (PT) and the 
Positive Outcome Expectancy (POE) subscale scores with the correlation between the BQ-JIA 
and the NOE subscale scores.  The correlation between the BQ-JIA and the patient-rated PT 
subscale score was not statistically significant (r = 0.271, p = 0.12), and the correlation with the 
POE subscale score was moderate and negative (r = -0.481, p = 0.003).  The nonsignificant 
correlation with the PT subscale score supported the conceptualization of barriers to adherence 
as a distinct construct from the patients’ perceived threat of unmanaged illness.  The negative 
correlation between the BQ-JIA and the POE subscale score suggested that patients’ perception 
of barriers was moderately but inversely related to their expectations regarding the benefits of 
medication taking.  These findings supported the divergent validity of the BQ-JIA. 
In contrast, the PBQ-JIA and PT subscale score from the BAMS-Parent measure were 
strongly and positively correlated (r = 0.497, p = 0.002), while the negative correlation between 
the PBQ-JIA and the POE subscale score was not significant (r = -0.259, p = 0.13).  These 
results suggested that the barriers constructs measured by the PBQ-JIA and the BQ-JIA may 
differ.   
Predictive validity.  
To determine the predictive validity of the BQ-JIA and PBQ-JIA, the barriers measures’ 
output variables (measured at Time 1) were correlated with pill count adherence and the 
corresponding participant-reported adherence estimates (measured at Time 2).  The BQ-JIA total 
of frequency scores significantly correlated with pill count adherence estimates (r = -0.372,        
p = 0.03); however, the PBQ-JIA number of barriers encountered in the week before Time 1 was 
not significantly correlated with pill count adherence estimates (r = -0.244, p = 0.16).  The BQ-
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JIA correlated with the Time 2 CARQ2 only at a trend level of significance (r = -0.335,               
p = 0.06), as did the PBQ-JIA and the Time 2 PARQ2 (r = -0.331, p = 0.09).  These results 
suggested that prediction of future adherence using the BQ-JIA was partially supported.  
However, the predictive validity of the PBQ-JIA was not supported, and incremental validity of 
the PBQ-JIA was not subsequently tested. 
Testing Hypothesis 3: Prediction of Significant Incremental Validity 
A hierarchical multiple regression analysis was used to evaluate the amount of variance 
in adherence that the BQ-JIA accounted for beyond that accounted for by demographic, disease, 
and medical regimen variables that demonstrated trend-level relationships (p < 0.20) with pill 
count adherence measured at Time 2.  In the first step of the regression model, the patient’s age 
at the time of study participation, the father’s age, the family’s annual income, and the combined 
HI score of the two parents were entered as the demographic variable predictors.  No disease-
related variables were correlated to adherence rates at a trend level.  In the second step of the 
regression model, the MRCI was entered as the sole regimen-related predictor. The BQ-JIA total 
frequency of barriers encountered in the week prior to Time 1 variable was entered in the third 
step.  The final model accounted for 39.1% of the variance in pill count adherence, and this 
represented a statistically significant amount of variance explained (F(6, 28) = 3.013, p = 0.02).  
The addition of the BQ-JIA to the model increased the portion of the variance in adherence rates 
accounted for by the model above that accounted for by the demographic and regimen-related 
predictors alone (ΔR2 =  0.180; F(1, 28) = 8.316, p = 0.007).  Within the final model, the BQ-JIA 
was the only predictor that uniquely accounted for a significant portion of variance in adherence 
rates (β = -0.025, t = -2.855, p = 0.004).  Table 9 summarized this model’s parameter estimates.  
The significant, negative regression coefficient associated with the BQ-JIA predictor variable 
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and the significant increase in the variance in adherence rates accounted for by the full model 
compared to the model without the BQ-JIA as a predictor provided support for the incremental 
validity of the barriers measure. 
Testing Hypothesis 4: Exploring the Relationship between Patient-reported and Parent-
reported Barriers 
To test the level of agreement between patients’ and parents’ reports of perceived 
barriers, the correlations for the following pairs of BQ-JIA and PBQ-JIA scores obtained at Time 
1 were calculated: total number of barriers ever encountered (r = 0.295, p = 0.08), number of 
barriers encountered in the past week (r = 0.459, p = 0.005), and total scale score (r = 0.554, p < 
0.001).  The moderate-to-strong positive correlations between patients’ and parents’ perceptions 
of the number and frequency of barriers encountered in the previous week indicated greater 
patient-parent reliability in rating more recently experienced barriers to adherence.  When the 
BQ-JIA and PBQ-JIA were administered at Time 2, patients’ and parents’ scores exhibited 
stronger correlations (rs ranged from 0.527 to 0.743, all ps ≤ 0.001).   
The individual barriers were ranked by the percentages of respondents who indicated 
having experienced each barrier at any time in the past, and these rankings were compared 
between the groups of patients and parents to identify similar and unique barriers perceived by 
the different participants (see Table 10). No imputed values were included in this analysis.  The 
majority of the barriers most frequently endorsed by patients were also frequently endorsed by 
parents, particularly barriers related to patient or parent forgetting, difficulty taking medication 
when away from home, and medication taste.  Forty percent of patients endorsed resistance to 
injection medications, while only 20% of parents endorsed this item, suggesting either different 
interpretations of the item (e.g., patients may have been reporting an aversion to injection 
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medications whether they had been prescribed one or not, while parents may have been reporting 
on instances of active avoidance of prescribed injection medications) or that patients may have 
been more likely to recall past instances of injection avoidance.  Altogether, these findings 
suggested that the BQ-JIA and the PBQ-JIA elicited fairly concordant perceptions of adherence 
barriers between patients and parents.  
Testing Hypothesis 5: Predicted Opposite Effects of Patient Age on the Relationships 
between Patient-reported Barriers and Adherence and between Parent-reported Barriers 
and Adherence 
To examine the effect of patients’ age on the BQ-JIA and PBQ-JIA scores’ abilities to 
predict adherence, interaction terms representing moderating effects of age on barriers scores in 
two multiple regression models of adherence were compared.  In the first model, the patient-
reported total frequency of barriers encountered in the past week (BQ-JIA at Time 1), patient 
age, and a term representing the interaction of the BQ-JIA variable and patient age were entered 
in the model as predictors of adherence measured by pill count.  The second model included the 
parent-reported number of barriers encountered in the past week (PBQ-JIA at Time 1), patient 
age, and the interaction between the PBQ-JIA variable and patient age as predictors of adherence 
measured by pill count.  The predictors were mean-centered to decrease the effects of 
multicollinearity.  In the first model, the interaction term was not a significant, unique predictor 
of adherence (β = 0.006, t = 1.33, p = 0.18), indicating that patient age did not moderate the 
relationship between patient-reported barriers and medication adherence.  Please see Table 11 for 
a summary of this model’s regression coefficient estimates.  In the second model, the interaction 
term was a significant, unique predictor of adherence (β = 0.012, t = 2.24, p = 0.02).  Please see 
Table 12 for a summary of this model’s regression coefficient estimates.  The positive regression 
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coefficient for the interaction term indicated that as patient age increased, the negative 
relationship between parent-reported number of barriers and adherence assessed by pill count 
decreased in magnitude.  In other words, the ability to predict adherence using parent-reported 
barriers weakened as the patient’s age increased.  The simple slopes illustrating this interaction 
between patient age and parent-reported barriers were plotted in Figure 2.  
Discussion 
 This pilot study provided initial psychometric data for the BQ-JIA and the PBQ-JIA and 
preliminary support for their clinical utility as brief, self-report measures of barriers to 
medication taking.  The low internal consistency of the BQ-JIA and the identification of three 
items exhibiting skewed response distributions, low item-total correlations, and high inter-item 
correlations suggested the need for further refinement of this measure.  The PBQ-JIA 
demonstrated adequate internal consistency that was comparable to values reported for other 
barriers scales in the pediatric adherence literature, though future analyses of the measure’s 
factor structure may reveal groups of items that represent more homogenous constructs within 
the barriers construct.  Both the BQ-JIA and the PBQ-JIA demonstrated adequate test-retest 
reliability, and the results of this study provided support for their validity through the 
associations between the barriers measures and concurrent measures of adherence and measures 
of constructs posited in the Health Belief Model.   
The specific output variables of the parent and patient barriers measures and their 
relationships to measures of adherence suggested the possibility that the barriers construct was 
measured differently in the group of patients compared to the group of parents.  The slightly 
stronger relationships between the parent-reported number of barriers encountered in the past 
week and parents’ ratings of their children’s general levels of difficulty with medication as well 
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as overall medication adherence compared to the relationships between the other PBQ-JIA 
output variables and these other measures may indicate that parents’ awareness of specific 
barriers but not necessarily the frequency at which barriers are encountered inform their 
perceptions of their children’s adherence.  Remarks that parents made when asked to record any 
barriers in addition to those listed in the PBQ-JIA indicated that several expected their older 
adolescents to take primary responsibility for taking medications, and this decrease in the 
parental role of monitoring medication adherence could conceivably relate to decreased 
awareness of how frequently patients struggle with adherence barriers as well as explain the 
nonsignificant relationship between parent-reported barriers and a more objective measure of 
adherence (pill count).  The moderating effect of increasing patient age on a decrease in strength 
of the negative, predictive relationship between parent-reported barriers and adherence, as well 
as the support for the BQ-JIA’s predictive validity and incremental validity, provided support for 
this interpretation.   
The differing ways in which patient- and parent-reported barriers related to the constructs 
of perceived threat of illness condition and positive expectancies regarding medication taking 
also suggested differences in patients’ and parents’ conceptualizations of adherence barriers.  
The moderate, negative relationship between patients’ perceptions of positive outcomes 
associated with medication taking and their reports of adherence barriers suggested either that a 
lack of perceived benefits represented a type of barrier to medication adherence or that barriers 
to adherence may diminish patients’ perceptions of the benefits of medication taking, either of 
which could decrease motivation to be adherent.  In contrast, parents’ positive outcome 
expectancies appeared more independent of their perception of adherence barriers, which were 
more closely related to their perceptions of illness threat.  It has been previously reported that 
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perceived threat and adherence were negatively related in adolescents with asthma (Riekert & 
Drotar, 2002), so perhaps the positive relationship between the PBQ-JIA measure and the PT 
subscale reflected a higher salience of illness severity and patient susceptibility in parents of 
nonadherent patients who encounter a number of barriers to adherence.  These plausible 
differences in patients’ and parents’ perceptions of barriers as well as the differing ability of the 
barriers measures to predict adherence support the recommendation of assessing and including 
both perspectives when clinicians collaborate with families to design interventions to target 
specific adherence barriers. 
Limitations 
 A major limitation of this study was the small sample size and attrition of eligible 
families at different stages of the study.  Though efforts were made to recover missing data and 
to multiply impute missing values to retain statistical power, parameter estimates derived from a 
sample of 35 would need to be replicated in a larger study for greater assurance of their 
reliability.  Also, the small sample size potentially limited the variability in responses to 
measures and in the range of sampled medication adherence rates compared to adherence rates in 
the population of patients with JIA.   
 Though multiple measures of adherence were employed in this study, including a more 
“objective” measure, participant-reported adherence rates may have overestimated actual 
adherence because of social desirability effects and problems with recall, and pill count estimates 
of adherence would not have distinguished between actual ingestion, misplacement, or dumping 
(Rapoff, 2010).  Additionally, estimates of adherence may have been affected by the families’ 
participation in a study explicitly focusing on medication adherence so that they were not 
representative of the patients’ general adherence rates (i.e., reactivity effect).  In a future study, 
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the use of a less obtrusive adherence measure, such as an electronic monitoring device, over a 
longer period of time may minimize the effects of reactivity and recall biases, though it would 
still be susceptible to medication dumping.  
 The poor internal consistency of the BQ-JIA represented another limitation of study 
results pertaining to this measure.  Though this pilot study provided support for the validity of 
this measure, further refinement of the BQ-JIA and evidence of improved measurement 
reliability would be required before the validity of the measure can be more firmly established.  
 The patients’ responses to the item on the BQ-JIA assessing for resistance to injections 
indicated that changing the stem of the item would promote more accurate reporting.  Although 
40% of patients endorsed this item, only 17% of the patients were prescribed a medication 
administered through injection during the study period.  Changing the stem to indicate that only 
patients who are prescribed injection medications should respond to the item may assist 
respondents in consistently interpreting the item. 
Future Directions 
 This pilot study has provided preliminary support for the reliability and validity of the 
BQ-JIA and PBQ-JIA as measures of patients’ and parent’s perceptions of recently encountered 
barriers to medication adherence.  These measures would benefit from further refinement 
through exploratory factor analysis to determine factor structure as well as to identify items that 
do not contribute to the purpose of barriers measurement.  Subsequent confirmatory factor 
analysis would provide additional support for the measures’ factor structure.  Given that roughly 
100 adolescents with JIA who were prescribed at least one daily medication were seen over the 
course of one year through one major hospital’s pediatric rheumatology clinic, it would be 
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beneficial to conduct a multisite study so that multivariate analyses like an exploratory factor 
analysis could be adequately powered. 
 After further measure development, the sensitivity of the BQ-JIA and the PBQ-JIA to 
changes in barriers and adherence could be tested within the context of an adherence 
improvement intervention study.  Demonstration that these barriers measures can assist in the 
identification of specific, modifiable adherence barriers as well as in monitoring the effects of 
interventions targeting these barriers would lend support to the routine use of these measures in 
clinical settings.   
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M
an
ag
e-
m
en
t 
S
u
rv
e
y
 
(I
M
S
) 
 
P
at
ie
n
t 
ra
te
s 
o
n
 L
ik
er
t 
sc
al
e 
le
v
el
 o
f 
ag
re
em
en
t 
w
it
h
 l
is
te
d
 
b
ar
ri
er
s 
(s
tr
o
n
g
ly
 
d
is
a
g
re
e,
 
d
is
a
g
re
e,
 
n
eu
tr
a
l,
 
a
g
re
e,
 
st
ro
n
g
ly
 
a
g
re
e)
 
2
7
 
It
em
s 
re
fl
ec
te
d
 
em
p
ir
ic
al
ly
 
su
p
p
o
rt
ed
 
b
ar
ri
er
s 
to
 
ad
h
 a
m
o
n
g
 
ad
o
le
sc
en
ts
 
w
it
h
 c
h
ro
n
ic
 
il
ln
es
s 
g
en
er
at
ed
 
fr
o
m
 
li
te
ra
tu
re
 
re
v
ie
w
; 
it
em
s 
w
er
e 
in
te
n
d
ed
 t
o
 
ap
p
ly
 t
o
 
ra
n
g
e 
o
f 
ch
ro
n
ic
 
il
ln
es
se
s 
T
o
ta
l 
sc
al
e 
sc
o
re
 
ra
n
g
e
: 
2
7
-1
3
5
: 
h
ig
h
er
 s
co
re
 
re
fl
ec
ts
 g
re
at
er
 
p
er
ce
iv
ed
 
b
ar
ri
er
s;
 5
 
su
b
sc
al
es
b
 
(C
ro
n
b
ac
h
's
 α
; 
#
 
it
em
s)
: 
d
is
ea
se
/r
eg
im
en
/ 
m
ed
ic
al
 s
y
st
em
s 
(0
.7
8
; 
7
),
 
co
g
n
it
iv
e 
d
if
fi
cu
lt
ie
s 
(0
.7
9
; 
7
),
 l
ac
k
 o
f 
so
ci
al
 s
u
p
p
o
rt
 o
r 
se
lf
-e
ff
ic
ac
y
 
(0
.7
4
; 
6
),
 
d
en
ia
l/
d
is
tr
u
st
 
(0
.6
5
; 
5
),
 
p
ee
r/
fa
m
il
y
 
is
su
es
 (
0
.5
6
; 
4
) 
   
5
-1
0
 
m
in
s 
N
 =
 1
5
2
 
p
at
ie
n
ts
 
w
it
h
 a
st
h
m
a 
(1
1
-1
8
 y
rs
 
o
ld
) 
In
te
rn
al
 
co
n
si
st
en
cy
: 
C
ro
n
b
ac
h
's
 
α
 =
 0
.8
7
; 
T
es
t-
re
te
st
 
re
li
ab
il
it
y
 (
4
 
w
ee
k
s)
: 
r 
=
 
0
.8
8
 
C
o
n
cu
rr
en
t 
v
al
id
it
y
: 
S
ca
le
 s
co
re
 
n
eg
at
iv
el
y
 
co
rr
el
at
ed
 
w
it
h
 h
ea
lt
h
 
ca
re
 p
ro
v
id
er
 
ra
te
d
 a
d
h
 t
o
 
tx
 
co
m
p
o
n
en
ts
; 
p
o
si
ti
v
el
y
 
co
rr
el
at
ed
 
w
it
h
 p
ro
v
id
er
 
ra
te
d
 a
st
h
m
a 
se
v
er
it
y
, 
a
g
e,
 
A
d
o
le
sc
en
t 
R
is
k
 T
ak
in
g
 
S
u
rv
e
y
 s
co
re
, 
an
d
 p
at
ie
n
ts
' 
P
er
ce
p
ti
o
n
s 
o
f 
A
st
h
m
a 
M
ed
 S
ca
le
 
sc
o
re
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u
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u
t 
T
im
e 
to
 
co
m
p
le
te
 
P
ar
ti
ci
p
an
ts
 
st
u
d
ie
d
 
R
el
ia
b
il
it
y
 
V
al
id
it
y
 
M
o
d
i 
&
 
Q
u
it
tn
er
 
(2
0
0
6
):
 
B
ar
ri
er
s 
to
 
A
d
h
er
en
ce
 
In
te
rv
ie
w
 -
 
A
st
h
m
a:
 
ch
il
d
 a
n
d
 
p
ar
en
t 
v
er
si
o
n
s 
 
In
te
rv
ie
w
ee
 
id
en
ti
fi
es
 
b
ar
ri
er
s 
to
 t
x
s 
(a
ls
o
 c
an
 
se
le
ct
 f
ro
m
 
li
st
 o
f 
2
5
 
co
m
m
o
n
 
b
ar
ri
er
s)
, 
ra
n
k
s 
b
ar
ri
er
s 
fo
r 
ea
ch
 t
x
, 
an
d
 r
at
es
 f
re
q
 
o
f 
ea
ch
 b
ar
ri
er
 
o
n
 L
ik
er
t 
sc
al
e 
(1
 =
 v
er
y 
ra
re
ly
, 
2
 =
 
o
n
ce
 p
er
 
m
o
n
th
, 
3
 =
 
tw
ic
e 
p
er
 
m
o
n
th
, 
4
 =
 
o
n
ce
 p
er
 
w
ee
k,
 5
 =
 
tw
ic
e 
p
er
 
w
ee
k,
 6
 =
 
m
o
re
 t
h
a
n
 
tw
ic
e 
p
er
 
w
ee
k,
 7
 =
 
d
a
il
y)
 
8
 s
p
ec
if
ic
 
tx
s 
li
st
ed
; 
n
o
t 
al
l 
tx
s 
w
er
e 
ap
p
li
ca
b
le
 
to
 a
ll
 
p
ar
ti
ci
p
an
t
s 
L
is
t 
o
f 
2
5
 
co
m
m
o
n
 
b
ar
ri
er
s 
fr
o
m
 t
h
e 
li
te
ra
tu
re
 
an
d
 e
x
p
er
t 
re
v
ie
w
, 
in
cl
u
d
in
g
 
m
ed
ic
al
 
te
am
 
N
u
m
b
er
 o
f 
b
ar
ri
er
s 
id
en
ti
fi
ed
 f
o
r 
ea
ch
 t
x
 
co
m
p
o
n
en
t,
 
ra
n
k
in
g
 o
f 
b
ar
ri
er
s'
 r
el
at
iv
e 
im
p
o
rt
an
ce
, 
se
lf
-
re
p
o
rt
ed
 f
re
q
 o
f 
ea
ch
 b
ar
ri
er
's
 
o
cc
u
rr
en
ce
 
D
ep
en
d
s 
o
n
 
n
u
m
b
er
 
o
f 
p
re
sc
ri
b
e
d
 t
x
 
co
m
p
o
n
e
n
ts
; 
1
5
-
2
0
 m
in
s 
if
 m
o
st
 
co
m
p
o
n
e
n
ts
 
ap
p
li
ed
 
N
 =
 1
5
 
p
at
ie
n
ts
 
w
it
h
 a
st
h
m
a 
(1
0
-1
3
 y
rs
 
o
ld
),
 N
 =
 3
6
 
p
ar
en
ts
 o
f 
p
at
ie
n
ts
 
w
it
h
 a
st
h
m
a 
(6
-1
3
 y
rs
 
o
ld
) 
N
o
t 
re
p
o
rt
ed
 
C
o
n
cu
rr
en
t 
v
al
id
it
y
: 
m
o
d
er
at
e 
n
eg
at
iv
e 
co
rr
el
at
io
n
s 
b
et
w
ee
n
  
n
u
m
b
er
 o
f 
b
ar
ri
er
s 
an
d
 
ad
h
 t
o
 
in
h
al
ed
 
co
rt
ic
o
st
er
o
id
s 
an
d
 
p
u
lm
o
zy
m
e 
fo
r 
se
v
er
al
 
ad
h
 
m
ea
su
re
s,
 
p
o
si
ti
v
e 
co
rr
el
at
io
n
 
b
et
w
ee
n
 
p
at
ie
n
t-
re
p
o
rt
ed
 a
d
h
 
an
d
 n
u
m
b
er
 
o
f 
b
ar
ri
er
s 
fo
r 
ai
rw
ay
 
cl
ea
ra
n
ce
 a
n
d
 
en
zy
m
es
 –
 a
ll
 
at
 t
re
n
d
 l
ev
el
 
(n
o
t 
si
g
n
if
ic
an
t)
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ar
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d
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R
el
ia
b
il
it
y
 
V
al
id
it
y
 
C
y
st
ic
 F
ib
ro
si
s 
M
o
d
i 
&
 
Q
u
it
tn
er
 
(2
0
0
6
):
 
B
ar
ri
er
s 
to
 
A
d
h
er
en
ce
 
In
te
rv
ie
w
 -
 
C
y
st
ic
 
F
ib
ro
si
s:
 
ch
il
d
 a
n
d
 
p
ar
en
t 
v
er
si
o
n
s 
 
In
te
rv
ie
w
ee
 
id
en
ti
fi
es
 
b
ar
ri
er
s 
to
 t
x
s 
(a
ls
o
 c
an
 
se
le
ct
 f
ro
m
 
li
st
 o
f 
2
5
 
co
m
m
o
n
 
b
ar
ri
er
s)
, 
ra
n
k
s 
b
ar
ri
er
s 
fo
r 
ea
ch
 t
x
, 
an
d
 r
at
es
 f
re
q
 
o
f 
ea
ch
 b
ar
ri
er
 
o
n
 L
ik
er
t 
sc
al
e 
(1
 =
 v
er
y 
ra
re
ly
, 
2
 =
 
o
n
ce
 p
er
 
m
o
n
th
, 
3
 =
 
tw
ic
e 
p
er
 
m
o
n
th
, 
4
 =
 
o
n
ce
 p
er
 
w
ee
k,
 5
 =
 
tw
ic
e 
p
er
 
w
ee
k,
 6
 =
 
m
o
re
 t
h
a
n
 
tw
ic
e 
p
er
 
w
ee
k,
 7
 =
 
d
a
il
y)
 
9
 s
p
ec
if
ic
 
tx
s 
li
st
ed
; 
n
o
t 
al
l 
tx
s 
w
er
e 
ap
p
li
ca
b
le
 
to
 a
ll
 
p
ar
ti
ci
p
an
t
s 
L
is
t 
o
f 
2
5
 
co
m
m
o
n
 
b
ar
ri
er
s 
d
er
iv
ed
 
fr
o
m
 t
h
e 
li
te
ra
tu
re
 
an
d
 e
x
p
er
t 
re
v
ie
w
, 
in
cl
u
d
in
g
 
m
ed
ic
al
 
te
am
 
N
u
m
b
er
 o
f 
b
ar
ri
er
s 
id
en
ti
fi
ed
 f
o
r 
ea
ch
 t
x
 
co
m
p
o
n
en
t,
 
ra
n
k
in
g
 o
f 
b
ar
ri
er
s'
 r
el
at
iv
e 
im
p
o
rt
an
ce
, 
se
lf
-
re
p
o
rt
ed
 f
re
q
 o
f 
ea
ch
 b
ar
ri
er
's
 
o
cc
u
rr
en
ce
 
D
ep
en
d
s 
o
n
 
n
u
m
b
er
 
o
f 
p
re
sc
ri
b
e
d
 t
x
 
co
m
p
o
n
e
n
ts
; 
1
5
-
2
0
 m
in
s 
if
 m
o
st
 
co
m
p
o
n
e
n
ts
 
ap
p
li
ed
 
N
 =
 1
9
 
p
at
ie
n
ts
 
w
it
h
 C
F
 
(1
0
-1
3
 y
rs
 
o
ld
),
 N
 =
 3
7
 
p
ar
en
ts
 o
f 
p
at
ie
n
ts
 
w
it
h
 C
F
 (
6
 -
 
1
3
 y
rs
 o
ld
) 
N
o
t 
re
p
o
rt
ed
 
C
o
n
cu
rr
en
t 
v
al
id
it
y
: 
 
m
o
d
er
at
e 
n
eg
at
iv
e 
co
rr
el
at
io
n
s 
b
et
w
ee
n
  
n
u
m
b
er
 o
f 
b
ar
ri
er
s 
an
d
 
ad
h
 t
o
 
in
h
al
ed
 
co
rt
ic
o
st
er
o
id
s 
an
d
 
p
u
lm
o
zy
m
e 
fo
r 
se
v
er
al
 
ad
h
 
m
ea
su
re
s,
 
p
o
si
ti
v
e 
co
rr
el
at
io
n
 
b
/t
 p
at
ie
n
t-
re
p
o
rt
ed
 a
d
h
 
an
d
 n
u
m
b
er
 
o
f 
b
ar
ri
er
s 
fo
r 
ai
rw
ay
 
cl
ea
ra
n
ce
 a
n
d
 
en
zy
m
es
 –
 a
ll
 
at
 t
re
n
d
 l
ev
el
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u
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T
im
e 
to
 
co
m
p
le
te
 
P
ar
ti
ci
p
an
ts
 
st
u
d
ie
d
 
R
el
ia
b
il
it
y
 
V
al
id
it
y
 
E
p
il
ep
sy
 
M
o
d
i,
 
M
o
n
ah
an
, 
D
an
ie
ls
, 
&
 
G
la
u
se
r 
 
(2
0
1
0
):
 
P
ed
ia
tr
ic
 
E
p
il
ep
sy
 
M
ed
 S
el
f-
M
an
ag
em
e
n
t 
Q
u
es
ti
o
n
n
ai
re
 
(P
E
M
S
Q
) 
 
F
o
r 
b
ar
ri
er
s 
sc
al
e,
 p
ar
en
t 
ra
te
s 
o
n
 L
ik
er
t 
sc
al
e 
th
e 
fr
eq
 
o
f 
ea
ch
 l
is
te
d
 
b
ar
ri
er
s 
(1
 =
 
n
ev
er
, 
2
 =
 
se
ld
o
m
, 
3
 =
 
so
m
et
im
es
, 
4
 
=
 o
ft
en
, 
5
 =
 
a
lw
a
ys
);
 o
th
er
 
sc
al
es
 a
ss
es
s 
d
is
ea
se
 a
n
d
 t
x
 
k
n
o
w
le
d
g
e,
 
ad
h
 t
o
 m
ed
s,
 
an
d
 b
el
ie
fs
 
ab
o
u
t 
m
ed
 
ef
fi
ca
cy
 
           
2
7
 i
te
m
s 
in
 
P
E
M
S
Q
; 
8
 i
te
m
s 
in
 
b
ar
ri
er
s 
sc
al
e 
O
ri
g
in
al
 
it
em
s 
g
en
er
at
ed
 
b
as
ed
 o
n
 
ex
p
er
t 
ad
v
ic
e 
fr
o
m
 
p
ed
ia
tr
ic
 
ep
il
ep
to
lo
g
i
st
s 
an
d
 
n
u
rs
e 
p
ra
ct
it
io
n
er
s 
as
 w
el
l 
as
 
re
v
ie
w
 o
f 
p
ed
ia
tr
ic
 
li
te
ra
tu
re
 
B
ar
ri
er
s 
sc
al
e 
sc
o
re
 r
an
g
e
: 
8
 -
 
4
0
 (
re
v
er
se
 
sc
o
re
d
: 
h
ig
h
er
 
sc
o
re
s 
re
p
re
se
n
te
d
 
fe
w
er
 b
ar
ri
er
s)
 
5
-1
0
 
m
in
s 
N
 =
 1
1
9
 
p
ar
en
ts
 o
f 
p
at
ie
n
ts
 
w
it
h
 
ep
il
ep
sy
 (
2
-
1
4
 y
rs
 o
ld
) 
B
ar
ri
er
s 
sc
al
e'
s 
in
te
rn
al
 
co
n
si
st
en
cy
: 
C
ro
n
b
ac
h
's
 
α
 =
 0
.7
6
 
C
o
n
cu
rr
en
t 
v
al
id
it
y
: 
p
o
si
ti
v
e 
co
rr
el
at
io
n
s 
b
et
w
ee
n
 
b
ar
ri
er
s 
sc
al
e 
an
d
 M
E
M
S
 
ca
p
 a
d
h
 a
n
d
 
se
lf
-r
ep
o
rt
ed
 
ad
h
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b
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V
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H
u
m
an
 I
m
m
u
n
o
d
ef
ic
ie
n
cy
 V
ir
u
s 
(H
IV
) 
In
fe
ct
io
n
 
M
ar
h
ef
k
a 
et
 
al
. 
(2
0
0
6
):
  
2
4
-H
o
u
r 
R
ec
al
l 
In
te
rv
ie
w
 
(2
4
R
I)
 
In
te
rv
ie
w
ee
 i
s 
as
k
ed
 t
o
 
re
co
u
n
t 
p
at
ie
n
t’
s 
ac
ti
v
it
ie
s 
fr
o
m
 
th
e 
p
re
v
io
u
s 
d
a
y
, 
in
cl
u
d
in
g
 
re
g
im
en
-
re
la
te
d
 e
v
en
ts
, 
an
d
 i
s 
as
k
ed
 
to
 l
is
t 
“t
h
e 
th
in
g
s 
th
at
 
m
ad
e 
it
 
d
if
fi
cu
lt
 t
o
 
fo
ll
o
w
 t
h
e 
p
h
y
si
ci
an
’s
 
m
ed
ic
al
 
re
co
m
m
en
d
-
at
io
n
s 
d
u
ri
n
g
 
th
e 
p
re
v
io
u
s 
d
a
y
” 
an
d
 “
th
e 
th
in
g
s 
th
at
 
k
ep
t 
th
em
 
fr
o
m
 
fo
ll
o
w
in
g
 t
h
e 
re
co
m
m
en
d
-
at
io
n
s 
ex
a
ct
ly
 
d
u
ri
n
g
 t
h
e 
p
re
v
io
u
s 
d
a
y
”
 
2
 o
p
en
-
en
d
ed
 
q
u
es
ti
o
n
s 
ab
o
u
t 
ad
h
 
b
ar
ri
er
s 
A
d
ap
ta
ti
o
n
 
o
f 
2
4
R
I 
u
se
d
 t
o
 
as
se
ss
 
d
ia
b
et
es
 
re
g
im
en
 a
d
h
 
(J
o
h
n
so
n
, 
K
el
ly
, 
H
en
re
tt
a,
 
C
u
n
n
in
g
h
a
m
, 
T
o
m
er
, 
&
 
S
il
v
er
st
ei
n
, 
1
9
9
2
) 
 
N
u
m
b
er
 
d
es
cr
ip
ti
o
n
s 
o
f 
ad
h
 b
ar
ri
er
s 
ex
p
er
ie
n
ce
d
 
V
ar
ia
b
le
 
in
te
rv
ie
w
 
le
n
g
th
; 
3
 
p
h
o
n
e 
in
te
rv
ie
w
s 
d
u
ri
n
g
 a
 
2
-w
ee
k
 
p
er
io
d
 (
2
 
w
ee
k
d
ay
s
, 
1
 
w
ee
k
en
d
 
d
a
y
) 
N
 =
 5
1
 
ca
re
g
iv
er
s 
o
f 
p
at
ie
n
ts
 
p
er
in
at
al
ly
 
in
fe
ct
ed
 
w
it
h
 H
IV
 
(2
-1
2
 y
rs
 
o
ld
) 
 
N
o
t 
re
p
o
rt
ed
 
fo
r 
b
ar
ri
er
s 
it
em
s 
C
o
n
cu
rr
en
t 
v
al
id
it
y
: 
re
p
o
rt
 o
f 
1
+
 
b
ar
ri
er
(s
) 
w
er
e 
in
 
ag
re
em
en
t 
w
it
h
 
m
ea
su
re
s 
o
f 
v
ir
al
 l
o
ad
 
(k
ap
p
a)
 a
t 
a 
tr
en
d
 l
ev
el
 (
p
 
<
 0
.1
0
):
 4
3
%
 
se
n
si
ti
v
it
y
, 
7
9
%
 
sp
ec
if
ic
it
y
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k
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K
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A
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is
o
n
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B
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h
an
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, 
B
u
lt
er
y
s,
 
B
et
ti
ca
, 
T
ep
p
er
, 
&
 
A
b
ra
m
s 
(2
0
0
8
):
  
P
A
C
T
G
 
P
ed
ia
tr
ic
 
A
d
h
er
en
ce
 
Q
u
es
ti
o
n
n
ai
re
 M
o
d
u
le
 
2
 
In
te
rv
ie
w
ee
 i
s 
as
k
ed
 “
W
h
en
 
a 
d
o
se
 o
f 
y
o
u
r 
ch
il
d
’s
 m
ed
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 d
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 b
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b
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b
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b
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 p
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b
ed
 
m
ed
 
N
o
t 
re
p
o
rt
ed
 
N
 =
 1
2
7
 
ad
u
lt
 
ca
re
g
iv
er
s 
o
f 
ch
il
d
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 b
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 b
ar
ri
er
s 
w
as
 
as
so
ci
at
ed
 
w
it
h
 
ca
re
g
iv
er
-
re
p
o
rt
ed
 
n
o
n
ad
h
 
             
 
 
65 
A
u
th
o
r(
s)
 
(Y
ea
r)
: 
M
ea
su
re
 
F
o
rm
at
 
N
o
. 
it
em
s 
It
em
 O
ri
g
in
s 
M
ea
su
re
 O
u
tp
u
t 
T
im
e 
to
 
co
m
p
le
te
 
P
ar
ti
ci
p
an
ts
 
st
u
d
ie
d
 
R
el
ia
b
il
it
y
 
V
al
id
it
y
 
B
u
ch
an
an
 
et
 a
l.
 (
2
0
1
2
) 
†
, 
F
ar
le
y
 e
t 
al
. 
(2
0
0
8
)
‡
: 
P
1
0
4
2
S
 
C
h
il
d
/ 
A
d
o
le
sc
en
t 
Q
u
es
ti
o
n
n
ai
re
; 
P
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ra
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b
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p
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a
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d
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b
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 m
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re
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b
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P
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n
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b
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b
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b
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 f
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b
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b
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b
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b
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 c
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b
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at
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p
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at
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 b
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b
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b
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at
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b
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 b
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b
ar
ri
er
s 
      
‡
C
o
n
cu
rr
en
t 
v
al
id
it
y
: 
ab
se
n
ce
 o
f 
p
at
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b
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 l
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b
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at
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 p
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at
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b
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p
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d
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b
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 b
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p
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p
at
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b
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at
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p
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at
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p
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v
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at
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p
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ra
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b
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D
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u
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 b
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 p
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b
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d
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ra
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re
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 o
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re
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p
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b
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b
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 p
at
ie
n
t-
re
p
o
rt
ed
 s
id
e 
ef
fe
ct
s 
an
d
 
fa
m
il
y
 
co
n
fl
ic
t,
 
n
eg
at
iv
e 
co
rr
el
at
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 p
at
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u
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b
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d
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ra
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 p
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p
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 o
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p
ie
n
ts
 
(1
1
-2
1
 y
rs
 
o
ld
) 
In
te
rn
al
 
co
n
si
st
en
cy
: 
C
ro
n
b
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at
io
n
s 
b
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 p
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b
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at
ie
n
t/
p
ar
en
t
-r
ep
o
rt
ed
 
ad
h
er
en
t 
an
d
 
n
o
n
ad
h
 
g
ro
u
p
s 
 
 
69 
A
u
th
o
r(
s)
 
(Y
ea
r)
: 
M
ea
su
re
 
F
o
rm
at
 
N
o
. 
it
em
s 
It
em
 O
ri
g
in
s 
M
ea
su
re
 O
u
tp
u
t 
T
im
e 
to
 
co
m
p
le
te
 
P
ar
ti
ci
p
an
ts
 
st
u
d
ie
d
 
R
el
ia
b
il
it
y
 
V
al
id
it
y
 
Z
el
ik
o
v
sk
y
 
&
 S
ch
as
t,
 
(2
0
0
8
),
 
Z
el
ik
o
v
sk
y
, 
S
ch
as
t,
 
P
al
m
er
, 
&
 
M
e
y
er
s,
 
(2
0
0
8
):
 
M
ed
ic
al
 
A
d
h
er
en
ce
 
M
ea
su
re
 
(M
A
M
) 
 
In
te
rv
ie
w
ee
 
en
d
o
rs
es
 
b
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 m
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 b
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at
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m
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d
u
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o
w
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ad
h
 b
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at
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n
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1
 b
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o
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 c
o
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o
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A
M
 
w
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Table 4. Comparison of Study Completers and Non-completers 
 Completed T2  
(n = 32) 
Non-completers  
(n = 26) 
Test (df) p 
Recruitment Site: n (%)  χ
2
(1) < 0.001 0.99 
KUMC 11 (34) 9 (35)   
Outreach Clinic 21 (66) 17 (65)   
Gender: n (%) female 28 (88) 24 (92) χ
2
 (1) = 0.36 0.55 
Age: M (SD) 14.93 (2.20) 15.04 (2.01) t(56) = -0.20 0.84 
JIA diagnosis: n (%)   χ
2
 (5) = 2.71 0.74 
RF negative polyarthritis 16 (50) 14 (54)   
Spondyloarthropathy 5 (16) 3 (12)   
RF positive polyarthritis 4 (12) 2 (8)   
Oligoarthritis 3 (9) 3 (12)   
Enthesitis-related arthritis 3 (9) 1 (4)   
Systemic JIA 1 (3) 3 (12)   
Note. Abbreviations included JIA = Juvenile Idiopathic Arthritis, RF = rheumatoid factor. 
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Table 5. Study Sample Demographics and Medical Characteristics 
  n (%) M [mdn] (SD) Range 
Recruitment Site       
KUMC 12 (34)     
Outreach Clinic 23 (66)     
Patient's Gender (female) 30 (86)     
Patient's Age (years)   15.0 (2.2) 11.2-18.2 
Patient's Age at Time of Diagnosis (years)   11.4 (4.6) 1.5-17.6 
Patient's Ethnicity       
Biracial 6 (17)     
Caucasian 25 (71)     
Hispanic 2 (6)     
Middle Eastern 2 (6)     
Patient's Specific JIA Diagnosis       
RF negative polyarthritis 18 (51)     
Spondyloarthropathy 6 (17)   
RF positive polyarthritis 4 (11)     
Enthesitis-related arthritis 3 (9)     
Oligoarthritis 3 (9)     
Systemic JIA 1 (3)     
Number of Active Joints       
0 13 (37)     
1 8 (23)     
2 9 (26)     
3 1 (3)     
>5 3 (9)     
missing 1 (3)     
Number of Medications Prescribed for JIA   3.3 [3] (1.2) 1.0-6.0 
Number of Patients Prescribed Type of Medication       
Nonsteroidal Anti-inflammatory Drug 35 (100)     
Disease Modifying Antirheumatic Drug 30 (86)     
Corticosteroid 6 (17)     
Biological Disease Modifying Drug 6 (17)     
MRCI
a   12.9 (5.3) 5.5-28.5 
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  n (%) M [mdn] (SD) Range 
Adult Participant’s Relationship to Patient       
Mother 31 (89)     
Father 3 (9)     
Grandparent 1 (3)     
Parents' Age (years)       
Mother (or female caregiver)   41 (6) 29-52 
Father (or male caregiver)   44 (7) 29-58 
Patients Living in Two-Parent Household 29 (83)     
Parent Educational Achievement above HS diploma/GED       
Mother (or female caregiver) 29 (83)     
Father (or male caregiver) 25 (71)     
Annual Household Income       
< $25,000 2 (5.7)     
$25,000-$50,000 5 (14.3)     
$50,000-$75,000 9 (25.7)     
$75,000-$100,000 9 (25.7)     
> $100,000 7 (20.0)     
Did not disclose 3 (8.6)     
HI Score of Employed Parents       
Mother (or female caregiver) (n=13)   38 (11) 10-54 
Father (or male caregiver) (n=20)   35 (13) 10-54 
Household (n=20)   62 (24) 18-103 
Note. Demographics of participating families and medical characteristics of patients who completed Time 
1 measures.  Abbreviations included GED = General Educational Development, HI = Hollingshead Index, 
HS = high school, JIA = Juvenile Idiopathic Arthritis, KUMC = University of Kansas Medical Center, 
MRCI = Medical Regimen Complexity Index, RF = rheumatoid factor. 
 
a
The MRCI is calculated from weighting the effects of different routes of medication administration, 
dosing frequencies, and special instructions for all medications (prescribed and OTC for JIA and other 
conditions) and supplements a child is taking regularly. 
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Table 10. Most Commonly Endorsed Barriers by Patients and Parents at Time 1 
  Patients Parents 
Rank Barriers Item n (%) 
Endorsed 
Barriers Item n (%) 
Endorsed 
1 Patient forgets 26 (74) Parent was not there to remind 
patient 
26 (74) 
2 Parent was not there to 
remind patient 
21 (60) Patient forgets 22 (63) 
3 Hard to take medication 
when not at home 
17 (49) Hard to take medication when 
not at home 
12 (34) 
4 Medication taste 15 (43) Medication side effects 11 (31) 
 
5 Patient resists injections 14 (40) Medication taste - and -                                                   
Patient does not understand need 
for medications 
10 (29)
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Table 11. Multiple Regression Model Testing Moderating Effect of Patient Age on the 
Relationship between Patient-reported Barriers and Adherence (Pill Count). 
Predictor β t p 
Patient age† 0.027 1.941 0.052 
BQ-JIA† -0.022 -2.400 0.016 
Patient age† x BQ-JIA† 0.006 1.331 0.183 
Constant 0.823 28.379 <0.001 
Note. Abbreviations included BQ-JIA = Barriers Questionnaire-Juvenile Idiopathic Arthritis total 
frequency of barriers experienced in the week prior to Time 1. 
†Predictor was mean-centered. 
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Table 12. Multiple Regression Model Testing Moderating Effect of Patient Age on the 
Relationship between Parent-reported Barriers on Adherence (Pill Count). 
Predictor β t p 
Patient age† 0.023 1.630 0.725 
PBQ-JIA† -0.017 -1.425 0.154 
Patient age† x PBQ-JIA† 0.012 2.240 0.025 
Constant 0.821 28.095 <0.001 
Note. Abbreviations included PBQ-JIA = Parent Barriers Questionnaire-Juvenile Idiopathic 
Arthritis number of barriers experienced in the week prior to Time 1. 
†Predictor was mean-centered. 
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CONSORT Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram. 
Recruitment 
Time Two 
Time One 
Assessed for eligibility (n=596) 
Ineligible (n=487) 
 Outside target age range (n=232) 
 Not diagnosed with JIA (n=226) 
 No daily JIA medication (n=15) 
 Currently receiving psychological 
treatment (n=14) 
 
Eligible but not recruited (n=49) 
 Physician did not recommend for 
recruitment (n=7) 
  Declined to participate (n=9) 
  Other reasons (n=2) 
 Missed (n = 31) 
 
Reported interest in study (n = 60) 
Did not sign consent forms (n=14) 
Signed consent forms (n=46) 
 Consented but excluded due to incorrect 
diagnosis (n=2) 
 Consented and entered study (n = 44) 
Completed Time One (n=35) 
Lost to follow-up (unable to contact) (n=8) 
Discontinued participation (illness, time) (n= 1) 
 
Completed Time Two (n=32) 
Lost to follow-up (unable to contact) (n=2) 
Discontinued participation (interest) (n= 1) 
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Figure 2. Patient age moderated the effect of parent-reported number of barriers experienced in 
the week prior to Time 1 on adherence measured by pill count (y-axis).  Number of barriers (x-
axis) was mean-centered, and simple slopes were plotted at patient ages 17.1 (M + 1 SD, green), 
15.0 (M, red), and 12.8 (M – 1 SD, black) years.  The interaction was plotted using the “Simple 
intercepts, simple slopes, and regions of significance in MLR 2-way interactions” online utility 
(Preacher, Curran, & Bauer; http://www.quantpsy.org/interact/mlr2.htm). 
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Appendix A 
BQ – JIA2 
Patients with arthritis or joint pain find it hard at times to be consistent in taking medications prescribed by their 
doctor.  Below are some things (barriers) that make it hard for patients to be consistent in taking prescribed 
medications.  Please look at the list of barriers and for each, tell us 1) if you have ever experienced this barrier 
(please circle “yes” or “no”), and, if so, 2) how often you experienced this in the past seven days (please circle one 
of the possible choices).  Also, please write down any other barriers you have experienced that are not on the list. 
Thank you very much for filling out this form.   
  Have you ever 
experienced this? 
How often did you experience this in 
the past seven days? 
1. I just forget when to take my medications Yes   /   No Never   /   sometimes   /   often 
2. It is too hard to take my medications when I 
am not at home 
Yes   /   No Never   /   sometimes   /   often 
3. I get confused about how many pills of each 
kind of medication to take 
Yes   /   No Never   /   sometimes   /   often 
4. I feel physically worse when I take the 
medications 
Yes   /   No Never   /   sometimes   /   often 
5. The pills are too hard for me to swallow Yes   /   No Never   /   sometimes   /   often 
6. My parent(s) is/are not always there to 
remind me to take my medications 
Yes   /   No Never   /   sometimes   /   often 
7. The medications taste bad Yes   /   No Never   /   sometimes   /   often 
8. I am not sure that I need the medications Yes   /   No Never   /   sometimes   /   often 
9. I started to feel better and did not need the 
medications anymore 
Yes   /   No Never   /   sometimes   /   often 
10.  Several adults take care of me, and I am 
often in different places (daycare, school) 
Yes   /   No Never   /   sometimes   /   often 
11. I ran out of the medications Yes   /   No Never   /   sometimes   /   often 
12. The drug store ran out of the medications Yes   /   No Never   /   sometimes   /   often 
13. I try to avoid medications that involve 
injections 
Yes   /   No Never   /   sometimes   /   often 
14. Sometimes I just simply  won’t take the  
medications 
Yes   /   No Never   /   sometimes   /   often 
15. We did not refill my medications  because we  
did not have enough money 
Yes   /   No Never   /   sometimes   /   often 
16. It is hard to fit taking medications into what I 
do every day 
Yes   /   No Never   /   sometimes   /   often 
17. I do not like the medications’ side effects Yes   /   No Never   /   sometimes   /   often 
18. I do not understand why I need to take my 
medications when I am feeling well Yes   /   No Never   /   sometimes   /   often 
Are there any other things that get in the way of taking medications that were not on this list?  If yes, please write 
them down here. 
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PBQ – JIA3 
Parents of children with arthritis or joint pain find it difficult at times to help their children be consistent in taking 
medications prescribed by the doctor.  Below are some things (barriers) that make it difficult to help children be 
consistent in taking prescribed medications.  Please review the following list of barriers and for each, tell us 1) if 
you have ever encountered this barrier (please circle “yes” or “no”), and, if so, 2) how often you experienced this 
in the past seven days (please circle one of the possible choices).  Also, please write down any other barriers you 
have experienced that are not on the list. 
Thank you very much for filling out this form.   
  Have you ever 
experienced this? 
How often did you experience this in 
the past seven days? 
1. I just forget when to give my child 
medications 
Yes   /   No Never   /   sometimes   /   often 
2. It is too hard to give my child medications 
when we are not at home 
Yes   /   No Never   /   sometimes   /   often 
3. I get confused about how many pills of each 
kind to give to my child 
Yes   /   No Never   /   sometimes   /   often 
4. My child feels physically worse when he/she 
takes the pills 
Yes   /   No Never   /   sometimes   /   often 
5. The pills are too hard for my child to swallow Yes   /   No Never   /   sometimes   /   often 
6. I am not always there to remind my child to 
take medications 
Yes   /   No Never   /   sometimes   /   often 
7. My child says that the medication tastes bad Yes   /   No Never   /   sometimes   /   often 
8. I am not sure that my child needs medication Yes   /   No Never   /   sometimes   /   often 
9. My child started to feel better and did not 
need the medication anymore 
Yes   /   No Never   /   sometimes   /   often 
10. The child has multiple caregivers, and is often 
in different places (daycare, school, etc.) 
Yes   /   No Never   /   sometimes   /   often 
11. We ran out of medication Yes   /   No Never   /   sometimes   /   often 
12. The pharmacy ran out of medication Yes   /   No Never   /   sometimes   /   often 
13. My child resists medications that involve 
injections 
Yes   /   No Never   /   sometimes   /   often 
14. My child just simply refuses to take the  
medications 
Yes   /   No Never   /   sometimes   /   often 
15. I did not fill or refill my child’s medications 
because I could not afford it 
Yes   /   No Never   /   sometimes   /   often 
16. It is hard to fit giving my child medications 
into the family’s routine 
Yes   /   No Never   /   sometimes   /   often 
17. My child does not like the medications’ side 
effects 
Yes   /   No Never   /   sometimes   /   often 
18. My child does not understand why he/she 
needs to take the medications when he/she is 
feeling well. 
Yes   /   No Never   /   sometimes   /   often 
Are there any other things that get in the way of helping your child take medications that were not included in this 
list?  If yes, please elaborate. 
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Appendix B 
Participant Demographics Form 
Instructions: Please respond to the following questions by writing an “X” on the line next to the 
answer that best describes your family. 
How are you related to the child who will be participating in this study? 
_____ mother 
_____ father 
_____ grandparent 
_____ other (please describe: ________________________________________) 
With whom does the child live most of the time? 
_____ mother 
_____ father 
_____ grandparent 
_____ other (please describe: ________________________________________) 
What is your current marital status? 
_____ married 
_____ single 
_____ divorced 
Please describe the occupations of both parents: 
mother: _________________________  father: ___________________________ 
What is the highest grade level completed by the child’s mother?  
_____ less than 7th grade 
_____ junior high 
_____ partial high school; what was the highest grade completed? ________ 
_____ high school graduate or GED 
_____ some college or specialized training; how many years completed? ________ 
_____ college graduate; type of degree received? ________ 
_____ graduate/professional training; type of degree received? ________ 
What is the highest grade level completed by the child’s father?  
_____ less than 7th grade 
_____ junior high 
_____ partial high school; what was the highest grade completed? ________ 
_____ high school graduate or GED 
_____ some college or specialized training; how many years completed? ________ 
_____ college graduate; type of degree received? ________ 
_____ graduate/professional training; type of degree received? ________ 
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Gender of the child participating in the study: 
_____ male 
_____ female 
Ethnicity of the child participating in the study: 
_____ African American 
_____ Asian American 
_____ Caucasian 
_____ Hispanic 
_____ Other (please describe: __________________________________________) 
Date of birth of the child participating in the study: ____________________ 
Age of child at time of diagnosis with Juvenile Idiopathic Arthritis: ______________________ 
Age of mother: __________    Age of father: __________ 
How many children are currently living in the household? ____________ 
What are their ages? ___________________________________ 
How many are receiving treatment for chronic diseases? ___________ 
Household income (yearly): 
_____ less than $10,000  
_____ $10,000 - $30,000 
_____ $30,000 - $50,000 
_____ $50,000 - $70,000 
_____ $70,000 - $100,000 
_____ more than $100,000 
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Appendix C 
Hollingshead Revised Form (Wasser, 1992) 
Hollingshead Index of Occupational Status Scale 
(1) Farm Laborers/Menial Service Workers 
(2) Unskilled Workers 
(3) Machine Operators and Semiskilled Workers 
(4) Smaller Business Owners, Skilled Manual Workers, Craftsmen, and Tenant Farmers 
(5) Clerical and Sales Workers, Small Farm and Business Owners 
(6) Technicians, Semiprofessionals, Small Business Owners 
(7) Smaller Business Owners, Farm Owners, Managers, and Minor Professions 
(8) Administrators, Lesser Professionals, Proprietors of Medium Sized Businesses 
(9) Higher Executives, Proprietors of Large Businesses, and Major Professionals 
Hollingshead Index Education Scale 
(0) Less than High School (K-11) 
(1) High School Degree or GED through partial college (12-15) 
(2) Standard College Degree (16-17) 
(3) Graduate Degree including Masters and Doctorate 
 
Calculation 
Parent #1 Scale Score Factor Weight Score x Weight 
Occupation  X5 = 
Education  X3 = 
  Total score #1 = 
Parent #2 Scale Score Factor Weight Score x Weight 
Occupation  X5 = 
Education  X3 = 
  Total score #2 = 
  Sum of Total Scores #1 & #2 (HI-R) = 
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Appendix F 
CARQ-JIA4 
1. Place a vertical mark (|) on the line below where it best represents how hard you found it to 
take your medication(s) in the past week: 
 
       Very easy                       Very hard 
 
2.  Place a vertical mark (|) on the line below where it represents the best how often you took your 
medication(s) in the past week: 
 
  
    Never                         Always 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
4
 Adapted from De Civita, Dobkin, Ehrmann-Feldman, Karp, and Duffy (2005)’s Child Adherence Report 
Questionnaire – Juvenile Idiopathic Arthritis.  The original item stems referred to medications, exercises, and splint 
wearing and were modified to refer only to medications for this measure. 
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PARQ-JIA5 
1. Please place a single vertical mark (|) on the line below at the level which best describes your 
child’s general level of difficulty in taking his/her medication(s) in the past week: 
 
       Very easy                        Very hard 
 
2.  Please place a single vertical mark (|) on the line below at the level which best describes how 
often your child followed treatment recommendations as prescribed (i.e., dosage, frequency) by 
the health care provider in the past week: 
 
  
    Never                         Always 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
5 Adapted from De Civita, Dobkin, Ehrmann-Feldman, Karp, and Duffy (2005)’s Parent Adherence Report 
Questionnaire – Juvenile Idiopathic Arthritis.  The original item stems referred to medications, exercises, and splint 
wearing and were modified to refer only to medications for this measure.  Also, item stems were changed from 
“past three months” to “past week” to match child version’s stem 
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Appendix G 
Beliefs About Medication Scale – Patient Form6 
Please rate how much you agree or disagree with each statement using the following rating scale: 
(1)  (2)  (3)  (4)  (5)  (6)  (7) 
Disagree  Disagree  Disagree  Neither Agree    Agree     Agree     Agree 
Completely    Mostly     a Little    nor Disagree     a Little      Mostly              Completely 
1. My friends think I should take my medicine the way the doctor says I should………………………. (1) (2) (3) (4) (5) (6) (7) 
2. When I take my medicine the way the doctor says I should, I feel like I am doing something                                             
good for my health……………………………………………………………………………………. (1) (2) (3) (4) (5) (6) (7) 
3. I do not think my illness is a serious illness…………………………………………………………... (1) (2) (3) (4) (5) (6) (7) 
4. If I take my medicine the way the doctor says I should, it gets in the way of me living my life  
the way I want………………………………………………………………………………………….(1) (2) (3) (4) (5) (6) (7) 
5. The side effects of my medicine are so bad that I do not want to take it……..………………………. (1) (2) (3) (4) (5) (6) (7) 
6. My illness gets in the way of finishing my school work……………….……..………………………. (1) (2) (3) (4) (5) (6) (7) 
7. I worry about health problems I might have if I do not take my medicine the way I should……...…. (1) (2) (3) (4) (5) (6) (7) 
8. I am sure that I can take my medicine the way the doctor says I should…………………………..…. (1) (2) (3) (4) (5) (6) (7) 
9. If I do not take my medicine the way I should, I will get sicker…………………………………...…. (1) (2) (3) (4) (5) (6) (7) 
10. I worry that my illness may get in the way of me doing the things I want to do in the future….....…. (1) (2) (3) (4) (5) (6) (7) 
11. If I take my medicine the way the doctor says I should, it makes me feel sicker……………….....…. (1) (2) (3) (4) (5) (6) (7) 
12. As long as I feel well, my illness is not a problem……………………………………………………. (1) (2) (3) (4) (5) (6) (7) 
13. It is often annoying for me to take my medicine the way the doctor says I should…………………... (1) (2) (3) (4) (5) (6) (7) 
14. Even if I got sicker, it would not change my life very much…………………………………………. (1) (2) (3) (4) (5) (6) (7) 
15. My family thinks I should take my medicine the way the doctor says I should…………………...…. (1) (2) (3) (4) (5) (6) (7) 
16. It is embarrassing for me to take my medicine in front of people I do not know well…………….…. (1) (2) (3) (4) (5) (6) (7) 
17. It is stressful to take my medicine the way the doctor says I should…………………………………. (1) (2) (3) (4) (5) (6) (7) 
18. I worry about getting sicker than I am right now…………………………………………………..…. (1) (2) (3) (4) (5) (6) (7) 
19. My illness gets in the way of me having fun with my friends……………………………………..…. (1) (2) (3) (4) (5) (6) (7) 
20. People in my life care if I take my medicine the way I should…………………………………….…. (1) (2) (3) (4) (5) (6) (7) 
21. It takes too much time to take my medicine the way the doctor says I should…………………….…. (1) (2) (3) (4) (5) (6) (7) 
22. I worry less about my health if I take my medicine the way I should……………………………..…. (1) (2) (3) (4) (5) (6) (7) 
23. My illness gets in the way of me doing things I want to do………………………………………..…. (1) (2) (3) (4) (5) (6) (7) 
24. I am sure that I can take my medicine the way the doctor says I should even if there are other  
things I want to do..…………………………………………………………………………………….(1) (2) (3) (4) (5) (6) (7) 
25. If I do not take my medicine the way I should, I could die………………………………………...…. (1) (2) (3) (4) (5) (6) (7) 
26. I feel different from other children/teenagers because I have to take medicine………………..….…. (1) (2) (3) (4) (5) (6) (7) 
27. It is easy for me to take my medicine the way the doctor says I should………………………..….…. (1) (2) (3) (4) (5) (6) (7) 
28. I feel pressure from my friends to skip taking my medicine……………………………………….…. (1) (2) (3) (4) (5) (6) (7) 
 
                                                             
6 © Riekert & Drotar (2002) 
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Please rate how much you agree or disagree with each statement using the following rating scale: 
(1)  (2)  (3)  (4)  (5)  (6)  (7) 
Disagree  Disagree  Disagree  Neither Agree    Agree     Agree     Agree 
Completely    Mostly     a Little    nor Disagree     a Little      Mostly              Completely 
29. Other people with my illness get very sick even if they take their medicine the way  
the doctor says they should..……………………………………………………………………..…….(1) (2) (3) (4) (5) (6) (7) 
30. I have a lot to gain from taking my medicine the way the doctor says I should……………………….(1) (2) (3) (4) (5) (6) (7) 
31. Taking my medicine the way I should makes me miss out on doing fun things……………………....(1) (2) (3) (4) (5) (6) (7) 
32. I am sure that I can take my medicine the way the doctor says I should even when my life  
is stressful..……………………………...………………………………………………………..…….(1) (2) (3) (4) (5) (6) (7) 
33. It upsets me to have to take medicine………………………………………………………………….(1) (2) (3) (4) (5) (6) (7) 
34. Even if people pressure me to skip a dose of my medicine, I will still take it…………………...…….(1) (2) (3) (4) (5) (6) (7) 
35. If I take my medicine the way the doctor says I should, it will keep me from getting sicker………….(1) (2) (3) (4) (5) (6) (7) 
36. I want to take my medicine the way the doctor says I should because it matters to people  
I care about..……………………………...…………………………………..…………………..…….(1) (2) (3) (4) (5) (6) (7) 
37. When I think about my illness I feel scared……………………………………………...…………….(1) (2) (3) (4) (5) (6) (7) 
38. I do not feel better even when I take my medicine the way the doctor says I should………………….(1) (2) (3) (4) (5) (6) (7) 
39. My family helps me take my medicine the way the doctor says I should…………………...………....(1) (2) (3) (4) (5) (6) (7) 
40. The good things that come from taking my medicine the way I should make the side effects  
worth it..……………………………...……………………………..………..…………………..…….(1) (2) (3) (4) (5) (6) (7) 
41. If I take my medicine the way the doctor says I should, it helps keep me feeling well….…………….(1) (2) (3) (4) (5) (6) (7) 
42. My illness gets in the way of me getting along with my family……………………………………….(1) (2) (3) (4) (5) (6) (7) 
43. I miss a lot of school because of my illness……………………………………………...…………….(1) (2) (3) (4) (5) (6) (7) 
44. Taking my medicine will keep me from having to go to the hospital………………………………….(1) (2) (3) (4) (5) (6) (7) 
45. Friends who are important to me care if I take my medicine……….………………………………….(1) (2) (3) (4) (5) (6) (7) 
46. I get out of doing things I do not want to do because I have to take medicine………………..……….(1) (2) (3) (4) (5) (6) (7) 
47. Taking my medicine the way the doctor says I should puts me in a bad mood………………..……....(1) (2) (3) (4) (5) (6) (7) 
48. My family knows if I take my medicine the way the doctor says I should………………..……..…….(1) (2) (3) (4) (5) (6) (7) 
49. When I take my medicine the way I should, I feel well enough to do things I enjoy………….……....(1) (2) (3) (4) (5) (6) (7) 
50. I think I will become sicker than I am right now……….………………..…………………………….(1) (2) (3) (4) (5) (6) (7) 
51. My friends help me take my medicine the way the doctor says I should………………………..…….(1) (2) (3) (4) (5) (6) (7) 
52. If I take my medicine the way I should, I miss fewer days of school…………………………....…….(1) (2) (3) (4) (5) (6) (7) 
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Beliefs About Medication Scale – Parent Form7 
Please rate how much you agree or disagree with each statement using the following rating scale: 
(1)  (2)  (3)  (4)  (5)  (6)  (7) 
Disagree  Disagree  Disagree  Neither Agree    Agree     Agree     Agree 
Completely    Mostly     a Little    nor Disagree     a Little      Mostly              Completely 
1. My friends think my child should take the medicine the way the doctor says he/she should…..……. (1) (2) (3) (4) (5) (6) (7) 
2. If my child takes the medicine the way the doctor says he/she should, My child feels like he/she is doing something                                             
good for his/her health………………...………………………………………………………………. (1) (2) (3) (4) (5) (6) (7) 
3. I do not think my child’s illness is a serious illness…………………………………………………... (1) (2) (3) (4) (5) (6) (7) 
4. If my child takes the medicine the way the doctor says he/she should, it gets in the way of him/her living life  
the way he/she wants…..……………………………………………………………………………….(1) (2) (3) (4) (5) (6) (7) 
5. The side effects of the medicine are bad enough that I do not want my child to take them…….……. (1) (2) (3) (4) (5) (6) (7) 
6. My child’s illness gets in the way of his/her finishing school work……………….…………………. (1) (2) (3) (4) (5) (6) (7) 
7. I worry about the health problems that my child might have if he/she does not take the medicine  
the way he/she should……...............................................................................................................…. (1) (2) (3) (4) (5) (6) (7) 
8. I am sure that my child can take the medicine the way the doctor says he/she should………….....…. (1) (2) (3) (4) (5) (6) (7) 
9. If my child does not take the medicine the way he/she should, he/she will get sicker……..……...…. (1) (2) (3) (4) (5) (6) (7) 
10. I worry that my child’s illness may get in the way of him/her doing the things he/she wants to  
do in the future…………………………………………………………………………………......…. (1) (2) (3) (4) (5) (6) (7) 
11. If my child takes the medicine the way the doctor says he/she should, it makes him/her feel sicker... (1) (2) (3) (4) (5) (6) (7) 
12. As long as my child feels well, his/her illness is not a problem…………...…………………………. (1) (2) (3) (4) (5) (6) (7) 
13. It is often inconvenient for my child to take the medicine the way the doctor says he/she should…... (1) (2) (3) (4) (5) (6) (7) 
14. Even if my child got sicker, it would not change his/her life very much………………………..……. (1) (2) (3) (4) (5) (6) (7) 
15. My family thinks my child should take the medicine the way the doctor says he/she should………... (1) (2) (3) (4) (5) (6) (7) 
16. It is embarrassing when my child has to take the medicine in front of people we do not know well… (1) (2) (3) (4) (5) (6) (7) 
17. It is stressful to help my child to take the medicine the way the doctor says he/she should.…………. (1) (2) (3) (4) (5) (6) (7) 
18. I worry about my child becoming sicker than he/she is right now……………….………………..…. (1) (2) (3) (4) (5) (6) (7) 
19. My child’s illness gets in the way of him/her having fun with friends………………………...…..…. (1) (2) (3) (4) (5) (6) (7) 
20. People in my life care if my child takes the medicine …………………………………………….…. (1) (2) (3) (4) (5) (6) (7) 
21. It takes too much time for my child to take the medicine the way the doctors tell us he/she should… (1) (2) (3) (4) (5) (6) (7) 
22. I worry less about my child’s health if he/she takes the medicine the way he/she should………...…. (1) (2) (3) (4) (5) (6) (7) 
23. My child’s illness gets in the way of him/her doing things he/she wants to do…………………....…. (1) (2) (3) (4) (5) (6) (7) 
24. I am sure that my child will be able to take the medicine the way the doctor says he/she should even if there are other  
things he/she wants to do..…….……………………………………………………………………….(1) (2) (3) (4) (5) (6) (7) 
25. If my child does not take the medicine the way he/she should, he/she could die…………..……...…. (1) (2) (3) (4) (5) (6) (7) 
26. My child feels different from other children/teenagers because he/she has to take medicine….….…. (1) (2) (3) (4) (5) (6) (7) 
27. It is easy for my child to take the medicine the way he/she should………………………….....….…. (1) (2) (3) (4) (5) (6) (7) 
28. I feel pressure from my friends to let my child skip doses of the medicine………………………..…. (1) (2) (3) (4) (5) (6) (7) 
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Please rate how much you agree or disagree with each statement using the following rating scale: 
(1)  (2)  (3)  (4)  (5)  (6)  (7) 
Disagree Disagree  Disagree  Neither Agree    Agree     Agree     Agree 
Completely    Mostly     a Little    nor Disagree     a Little      Mostly              Completely 
29. Other people with my child’s illness get very sick even if they take their medicine the way  
the doctor says he/she should..…………………………………………………………………..…….(1) (2) (3) (4) (5) (6) (7) 
30. My child has a lot to gain if he/she takes the medicine the way the doctor says he/she should……….(1) (2) (3) (4) (5) (6) (7) 
31. I feel like having to take medicine the way he/she should makes my child miss out on doing fun 
things…………………………………………………………………………………………...……....(1) (2) (3) (4) (5) (6) (7) 
32. I am sure that my child will be able to take the medicine the way the doctor says he/she should  
even when his/her life is stressful..……………………………...………………………………….….(1) (2) (3) (4) (5) (6) (7) 
33. It upsets me that my child to have to take medicine……………………………………..…………….(1) (2) (3) (4) (5) (6) (7) 
34. Even if people pressure my child to skip a dose of the medicine, he/she will take it………………….(1) (2) (3) (4) (5) (6) (7) 
35. If my child takes the medicine the way he/she should, it will keep him/her from getting sicker……...(1) (2) (3) (4) (5) (6) (7) 
36. I want my child to take the medicine the way the doctor says he/she should because it is important  
to people I care about..……………………………...…………………………………..………. …….(1) (2) (3) (4) (5) (6) (7) 
37. When I think about my child’s illness I feel scared……………………………………...…………….(1) (2) (3) (4) (5) (6) (7) 
38. My child does not feel better even when he/she takes the medicine the way the doctor says he/she 
should………………………………………………………………………………………….……….(1) (2) (3) (4) (5) (6) (7) 
39. My family provides me support to help my child take the medicine the way the doctor says he/she 
should…………………...………………………………………………………………………...…....(1) (2) (3) (4) (5) (6) (7) 
40. The good things that come from my child taking medicine the way he/she should make the side effects  
worth it..……………………………...……………………………..………..…………………..…….(1) (2) (3) (4) (5) (6) (7) 
41. If my child takes the medicine the way the doctor says he/she should, it helps keep him/her  
feeling well……………………………………………………………………………….…………….(1) (2) (3) (4) (5) (6) (7) 
42. My child’s illness gets in the way of my child getting along with the family…...…………………….(1) (2) (3) (4) (5) (6) (7) 
43. My child misses a lot of school because of his/her illness………………………………………….….(1) (2) (3) (4) (5) (6) (7) 
44. Taking his/her medicine will keep my child from having to go to the hospital…………………….….(1) (2) (3) (4) (5) (6) (7) 
45. Friends who are important to me care if my child takes the medicine……….………..……………….(1) (2) (3) (4) (5) (6) (7) 
46. My child gets out of doing things he/she does not want to do because he/she has to take medicine….(1) (2) (3) (4) (5) (6) (7) 
47. Taking his/her medicine the way the doctor says he/she should puts my child in a bad mood……......(1) (2) (3) (4) (5) (6) (7) 
48. My family notices if my child takes the medicine ………………………………………..……..…….(1) (2) (3) (4) (5) (6) (7) 
49. When my child takes the medicine the way he/she should he/she feels well enough to do things 
 he/she enjoys…………………………………………………………………………….…………….(1) (2) (3) (4) (5) (6) (7) 
50. I think my child will become sicker than he/she is right now……….………..………….…………….(1) (2) (3) (4) (5) (6) (7) 
51. My friends help me help my child take his/her medicine the way the doctor says he/she should……..(1) (2) (3) (4) (5) (6) (7) 
52. If my child takes the medicine the way he/she should, he/she misses fewer days of school…………..(1) (2) (3) (4) (5) (6) (7) 
 
 
 
 
